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CHAPTER I 
 
Introduction 
 
The immune system is broadly separated into two branches, referred to as the 
innate and adaptive immune system. The innate immune system recognizes what are 
termed pathogen-associated molecular patterns or PAMPs and provides a rapid general 
response to infections occurring anywhere throughout the body.  PAMPs are generally 
defined as chemical structures unique to classes of viruses and bacteria, such as 
lipopolysaccharide, double-stranded RNA, peptidoglycan, unmethylated CpG motifs, 
and peptidoglycans 1.  These structures are recognized by a series of sensors including 
toll-like receptors and other pattern recognition receptors present in eukaryotic 
organisms and stimulate a series of different signaling cascades resulting in expression 
of interferons and other cytokines that contribute to the control of viral and bacterial 
infections.  This innate immune response is also a strong activator of the adaptive 
immune response 2. 
The adaptive immune system is characterized by the ability to develop a specific 
immune response to a pathogen. The adaptive immune response is primarily comprised 
of lymphocytes, including antibody producing B cells and CD8+ and CD4+ T-cells 2–5. 
Classically, T cell and B cell receptor genes undergo somatic gene rearrangement to 
create a clonal repertoire capable of recognizing any chemical structure expressed by 
invading pathogens. Both antibodies produced by B cells and T-cell receptors 
expressed by T-cells are highly specific for a given antigenic structure expressed by 
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pathogens and confer lifelong immunity to infection. Upon antigen recognition, 
lymphocytes massively proliferate and generate expanded clones with identical antigen 
receptors. Antigen-specific CD8+ T-cells recognize specific viral antigens and are 
cytotoxic for cells infected by specific viruses 3,6. Antigen-specific CD4+ T-cells, or T 
helper cells, produce an array of signaling molecules called cytokines in response to 
infection that orchestrate the adaptive immune response 5.  
 
Helper T-cell Polarization 
Helper T-cells are also sub-divided into naïve, effector and memory T-cells 4.  
Upon encounter with their specific antigen, naïve T-cells proliferate via IL-2 but do not 
express the cytokines critical for orchestrating the adaptive immune response 7. The 
cytokine microenvironment during antigen encounter dictates T helper cell polarization. 
CD4+ helper T-cells differentiate into several classes of effector T-cells that are defined 
by the cytokines they produce and how they defend against infection 8.  Examples 
include effector T helper 1 (TH1) cells that produce IFN-γ, TH2 cells that produce IL-4, 
IL-5, and IL-13, TH17 cells that produce IL-17, T follicular helper (Tfh) cells that help B 
cells produce antibody against foreign pathogens, and T regulatory (Treg) cells which 
regulate immunity through anti-inflammatory IL-10 (Figure 1.1).   
TH1 cells are defined by their production of the cytokine IFN-γ. IFN-γ plays a key 
role in controlling infection by both bacteria and viruses, but also acts as one of the first 
steps in TH1 cell polarization 9,10. IFN-γ, initially produced by innate immune cells, binds 
to naïve T cells and induces signal transducer and activator of transcription (STAT) 1 
expression 11. STAT1 is part of a family of transcription factors that help regulate  
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Figure 1-1. CD4+ T helper Cell Differentiation. Different subsets of T helper cells 
are polarized according to the soluble cytokines present during priming by an 
antigen-presenting cell (APC) (IL-12 and IFN-γ for TH1), a lineage defining 
transcription factor (T-bet for TH1), and a secreted cytokine to regulate a portion of 
the immune response (IFN-γ for TH1).  
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T helper cell polarization 12. STAT1 expression activates the T-box transcription factor 
(T-bet) 13,14. T-bet is referred to as the master transcriptional regulator of TH1 cells as it 
enhances expression of IFN-γ, creating a feed forward loop of IFN-γ and T-bet 
production 15,16. T-bet deficient cells are unable to mount a TH1 response even in 
proper polarizing conditions 17. T-bet also induces IL12Rβ2, one chain of the IL-12 
receptor 13. IL-12 binding leads to the expression of STAT4, another transcription factor 
necessary for IFN-γ production 18,19. T-bet and STAT4 work in tandem to induce IFN-γ 
expression by rearranging chromatin structure throughout the IFNG locus resulting in 
activation of gene transcription 20–23. IFN-γ expression is significantly reduced in STAT4 
deficient cells 24. The combined actions of the IFN-γ /STAT1/T-bet and the IL-12/STAT4 
pathways lead to complete TH1 polarization. 
TH2 cells are defined by the production of the cytokines IL-4, IL-5 and IL-13. 
Each of these cytokines have unique effects but are important for the immune response 
to helminth infection and play a role in allergy. Naïve T-cells polarize to TH2 cells by 
stimulation by IL-4, which induces the activation of STAT6 25–27.  STAT6 directly binds 
and induces transcription of the GATA3 gene, thought of as the master transcriptional 
regulator of TH2 polarization 28,29. Gata3 directs TH2 polarization by binding to the TH2 
cytokine gene locus, which contains the IL4, IL5 and IL13 genes 30. TH2 differentiation 
and responses are almost entirely abrogated in Gata3 deficient cells 30–32. However, 
Gata3 cannot regulate each cytokine gene effectively on its own and STAT6 activation 
is required for effective TH2 polarization 33. Gata3 not only rearranges chromatin around 
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the TH2 cytokine locus, but also directly binds the IL5 34and IL13 promoters 35,36. The 
combination of STAT6 and Gata3 is necessary for TH2 polarization.  
TH17 cells produce a greater diversity of cytokines, including IL-17a, IL-17e, IL-
17f, IL-21 and IL-22 37,38. IL-17 is a pro inflammatory signal involved in antifungal 
immunity at mucocutaneous surfaces. IL-17a and IL-17f are also involved in the 
pathogenesis of autoinflammatory and autoimmune disorders, including inflammatory 
bowel disease, psoriasis, and ankylosing spondylitis. TH17 cell polarization occurs in 
three transcriptional phases. T-cell activation in the presence of transforming growth 
factor-𝛃 (TGF-𝛃) and IL-6 drives the initial polarization of naive CD4+ T-cells to TH17 
cells 39,40. IL-6 activates STAT3, which helps induce expression of IL-21, and IL23R 41. 
STAT3 expression induces ROR𝜸t, referred to as the master transcriptional regulator of 
TH17 cells 42,43. Once ROR𝜸t is expressed, TH17 cells begin expressing hallmark 
cytokines like IL-17a and IL-17f. The second phase includes self-amplification by IL-21. 
Unlike TH1 and TH2 cells, the main TH17 cytokine does not amplify its differentiation. 
IL-21, which is produced by TH17 and innate immune cells, combines with TGF-𝛃 to 
amplify cell differentiation independent of IL-6 44,45. The final phase is IL-23 induced 
stabilization. IL23R expression occurs downstream of IL-6 and IL-21 and is further 
induced by IL-23 binding to its receptor 39,46. IL-23 does not expand or drive 
differentiation but is required for effective TH17 cell maintenance.  
Tfh cells are located in the follicular areas of lymphoid tissue and express B-cell 
promoting IL-21. The development of a Tfh from a naïve T-cell is slightly different from 
the other effector cells, as it must be trafficked to a germinal center. After T-cell receptor 
priming, naïve T-cells stimulated by IL-6 will express STAT3 12,47. STAT3, in the 
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absence of TGF-𝛃 binding will induce Bcl6, referred to as the master transcription 
factor, as well as IL-21 47. Bcl6 drives expression of CXCR5, the cell surface marker to 
allows Tfh cells to traffic to the B cell zone 48,49. Once inside the B cell zone, Tfh cells 
will bind to B cells via ICOS and the T-cell receptor to form germinal centers 50. Through 
prolonged interaction and varied cytokine secretion, Tfh cells contribute to class 
switching and memory formation by activated B cells 51. 
The regulatory T cells, or Tregs, are a distinct subset of CD4+ T cells which 
suppress effector cells in the periphery at sites of inflammation, primarily regulating the 
other CD4+ T cell populations 52. Tregs mediate immune responses by producing 
immunosuppressive cytokines like IL-10, IL-35 and TGF-𝛃, inducing cytolysis via 
granzyme A/B and perforin, and disrupting T cell metabolic function by IL-2 deprivation 
52. Tregs can either form in the thymus, called tTregs, and emerge as a fully matured 
cell population or develop in the periphery, called pTregs, from CD4+ naïve T cells 53. 
Tregs are characterized by constitutive expression of the transcription factor Forkhead 
box P3, FOXP3, as well as high expression of CD25 and low expression of CD127 52. 
During thymic selection, cells whose TCR bind with a moderate avidity to self-antigen, 
but still escape negative selection, will increase expression of CD25 and begin 
expressing FOXP3, referred to as the master transcriptional regulator of Tregs. Unlike 
other master transcription factors previously discussed, FOXP3 can be expressed at 
low levels in conventional inflammatory T cells without inducing the suppressive Treg 
functions 52. Treg development requires FOXP3 expression along with a cell specific 
hypomethylation pattern within a region called the Treg specific demethylated region or 
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TSDR 54. Only the combined expression of FOXP3 and epigenetic modification of the 
TSDR will induce Treg differentiation and immunosuppressive effects. 
Master transcription factors drive T helper cell polarization by activating a cell 
specific gene profile. However, each transcription factor also represses cytokines and 
transcription factors related to alternative T helper cell fates. T-bet not only activates 
TH1 lineage specific genes but also inhibits expression of the cytokine IL-4 22 and 
directly binds and sequesters Gata3 55. T-bet also blocks TH17 polarization by 
repressing ROR𝜸t expression. Gata3 represses IFN-γ expression by repressing STAT4 
and IL12Rβ2 mRNA transcription through chromatin remodeling 30,56. TGF-𝛃1 
suppresses the expression of T-bet and Gata3, inhibiting the naive CD4+ T-cell from 
adopting the TH1 or TH2 cell fates initially, but IL-23 can still induce IFN-γ expression 
later in development 57. TH17 cells both in-vitro and in-vivo have shown the ability to 
produce IFN-γ and IL-17a after polarization. The conversion of IL-17 producers to IFN-γ 
producing cells is an important aspect in immunopathogenesis in disease models, and 
likely in autoimmune disease 58. Tfh cells have been implicated in production of 
numerous other cytokines, including IFN-γ, IL-4, and IL-10 to regulate class switching in 
B cells 51.  
 In order to respond to the ever-evolving variety of pathogens, the human immune 
system must be heterogeneous and adaptable. The immune system must be able to 
mount the correct cellular response efficiently before an infection can irreparably 
damage tissue. Dynamic responses to extracellular signals allow a naïve T-cell to 
develop into the varied repertoire of effector T-cells described here, but our 
understanding of T-cell development is not complete. A better understanding of the 
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complex systems regulating TH cell development will contribute to our ability to activate 
the immune system to better fight infection as well as to better control the immune 
system when it is over-activated, for example, during autoimmune or other inflammatory 
diseases.  
 
Long Noncoding RNA 
Our understanding of gene regulation used to include the DNA sequence of a 
gene and the proteins bound within the gene region. The act of transcription produced 
an mRNA and was translated into a functional protein. The discovery of noncoding 
RNAs caused an immense shift in our understanding of RNA’s role in molecular biology. 
A larger portion of the human genome produces noncoding RNAs than mRNA genes. 
Several functional RNAs have been discovered including transfer RNA (tRNA), 
ribosomal RNA (rRNA), and even more recently long noncoding RNA (lncRNA).  
LncRNAs are >200bp in length (to distinguish them from smaller classes of 
RNAs, such as microRNAs) and possess little to no protein coding potential 59-61. 
LncRNA genes are transcribed by RNA Pol II, mostly receive a 5’ cap and a poly-A tail, 
and many contain introns that are spliced out like mRNA 62,63. LncRNAs are typically 
riddled with stop codons and contain no verifiable reading frame, separating them from 
mRNA 64. MicroRNAs and lncRNAs share some regulatory functions, but the processing 
and size of lncRNAs separate them from microRNAs. Functionally, many lncRNAs 
regulate expression of nearby protein-coding genes in the genome and therefore have 
been classified according to their genomic location relative to nearby protein-coding 
genes 60,63 (Figure 1.2). Four classes have emerged to define lncRNAs, including 
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antisense, intronic, intergenic, and divergent. Antisense lncRNAs are produced on the 
opposite strand of an mRNA gene, and in the opposite direction while sometimes 
overlapping in their transcriptional window. Intronic lncRNAs are produced almost 
entirely in the intron region of an mRNA gene. Intergenic lncRNAs are located between 
two mRNA genes, overlapping with neither gene and typically far from an mRNA gene. 
Finally, Divergent lncRNAs are produced on the opposite strand of an mRNA gene but 
are close enough they can share a promoter.  
The function of lncRNA transcripts have become better understood in large part 
from studies that deplete the lncRNA without interfering with its gene locus. LncRNAs 
can bind proteins, RNA, and DNA, which endows them several regulatory functions 63-
65. Regulation by lncRNA transcripts involve 3 major actions: Sequestering, guiding, and 
scaffolding (Figure 1-3).  
LncRNAs can bind proteins to sequester them from binding to their cognate DNA 
elements or to other proteins (Figure 1-3A). Often lncRNAs will contain a sequence 
motif like the DNA binding region in order to act as a decoy. For example, CTCF is a 
transcription factor that binds to promoter regions within multiple genes and is typically 
repressive 66. JPX, a lncRNA transcribed from the X chromosome inactivation center will 
bind CTCF and impair the ability of CTCF to bind the Xist gene promoter resulting in 
stimulation of Xist transcription, which is required for X-chromosome inactivation in 
females 67. Similarly, NF-YA is a transcription factor that activates genes that encode 
pro-apoptotic proteins in response to DNA damage. PANDA is a lncRNA that binds to 
the DNA-binding pocket of NF-YA thus sequestering NF-YA away from its cognate DNA 
binding enhancer elements 68. Another example is GAS5, a lncRNA that binds the  
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Figure 1-2 Anatomy of a LncRNA Loci. Antisense lncRNAs are transcribed from 
the opposite strand and overlap with its mRNA partner. Intronic lncRNAs initiate 
inside of an intron of a protein-coding gene. Intergenic lncRNAs are separate 
transcriptional units from protein-coding genes, occurring between two separate 
mRNAs irrelevant of distance. Divergent lncRNAs initiate on the opposite strand of its 
mRNA partner bidirectionally from a shared promoter region. 
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glucocorticoid receptors, thus preventing the glucocorticoid receptor from inducing 
transcription of its target genes 70. Finally, lncRNAs not only act on proteins, as some 
have been shown to bind microRNAs and have been referred to as microRNA 
“sponges” 71. MicroRNAs repress genes by binding mRNAs to either limit translation or 
degrade the mRNA via nuclease activity in the cytoplasm. LncRNAs bind to and 
sequester microRNAs through base pairing so they cannot bind to their target mRNAs 
72. 
 Another example of lncRNA function is to act as guides to recruit chromatin 
modifying complexes to both gene loci and DNA regulatory elements (Figure 1-3B). 
Chromatin, or packaged DNA, is made up of histone protein octamers wrapped in DNA, 
together called nucleosomes. The histone proteins, including H2A, H2B, H3 and H4, 
contain flexible N-terminal tails that are modified to tighten or relax the binding between 
the histone proteins and bound DNA 73,74. Patterns of histone modifications can be used 
to aid in the identification of active and inactive gene regions. Mono-, di-, and 
trimethylation of histone 3 lysine 9 (H3K9me1/2/3) and H3K27me1/2/3 are associated 
with transcriptional repression and inaccessible regions of DNA 75. Acetylation and other 
methylation modifications, such as H3K27ac or H3K4me3, are associated with active 
and accessible enhancers or promoters. Histone modifications are added by chromatin 
modifying complexes such as acetyltransferases and methyltransferases. Certain 
chromatin modifying proteins, like WDR5 and PRC2, depend on lncRNAs to guide them 
to target loci 76. WDR5 is a portion of the MLL methyltransferase that catalyzes 
formation of H3K4me1/2/3, a permissive chromatin mark found at active promoters and 
enhancers. WDR5 interacts with over 200 lncRNAs in Embryonic Stem Cells (ESC) and  
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Figure 1-3. Long noncoding RNA (lncRNA) function. (a) LncRNAs sequester DNA 
binding proteins to repress function. (b) LncRNAs can act as guides to recruit 
chromatin modifying complexes to specific DNA regions. (c)  LncRNAs may act as 
scaffolds to consolidate multiple protein complexes into a single unit.  
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has an identified RNA binding pocket 77. When the RNA-binding pocket is mutated, 
WDR5 no longer accumulates on chromatin nor functions to sustain methylation 
patterns around active genes. The lncRNA, HOTTIP, binds WDR5 and helps recruit it to 
the HOXA gene to promote transcription 81. Abrogation of HOTTIP lncRNA leads to 
decreased proliferation and apoptosis in ESCs 77,78. The Polycomb Repressive Complex 
(PRC) is a methyltransferase responsible for silencing genes, contributing to 
heterochromatin formation by adding H3K27me3 marks when it is recruited to genomic 
loci 79. In HeLa cells, ~20% of lncRNAs expressed in the cell are found to associate with 
the PRC2 complex 80. HOTAIR is a lncRNA required for proper localization of PRC2 
across the HOXD gene region 81. HOXD genes are de-repressed when HOTAIR 
lncRNA expression is abrogated, resulting from an increase in H3K4me3 marks and 
increased RNA Pol II occupancy at the HOXD gene locus 82. LncRNAs can bind and 
recruit either activating or repressive histone modifying complexes to regulate gene 
expression.  
HOTAIR is also an example of a lncRNA with multiple functions, as it helps 
scaffold the PRC2 and the LSD1-CoRest complex 83 (Figure 1-3C). The LSD1-CoRest 
complex is a demethylase, removing methyl groups from histone H3, such as the 
permissive H3K4me3 mark. By combining the LSD1-CoRest complex with the PRC2 
methyltransferase complex, HOTAIR lncRNA helps to form a complex that can 
simultaneously remove permissive marks and replace them with repressive chromatin 
marks to effectively silence a gene 83.  ANRIL, another lncRNA associated with the 
PRC, binds to subunits of both PRC1 and PRC2 to form a singular complex 84,85. A 
reduction in ANRIL transcripts significantly suppresses cell proliferation and leads to 
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apoptosis in osteosarcoma cell lines. As further studies continue, the unique versatility 
presented by lncRNAs will surely identify new functions of this diverse array of RNAs. 
LncRNAs not only regulate transcription through the functions of their RNA 
transcripts but can also regulate neighboring genes through the act of lncRNA gene 
transcription or by impacting RNA splicing. BLUSTR is a divergent lncRNA located next 
to the mRNA gene SFMBT2 86. SFMBT2 expression is repressed when BLUSTR 
transcription is disrupted but is not impacted by deletion of entire exons downstream of 
the BLUSTR start site. UPPERHAND (UPH) is another divergent lncRNA which 
regulates an mRNA gene partner independent of a specific sequence 87. UPH shares a 
promoter region with HAND2 and disrupting transcription by introducing a premature 
poly(A) signal impaired HAND2 expression. HAND2 was unaffected by reducing UPH 
transcripts via antisense oligonucleotides or inserting new sequences into the UPH 
gene locus. Cis-acting gene regulation by transcription or splicing is not unique to only 
lncRNAs, as mRNA pairs have shown similar regulatory action.  
Recently, a few lncRNAs have been implicated in the formation of R-Loops 88. An 
R-loop is the formation of a DNA-RNA-DNA triplex (Figure 1-4). R-loops occur in G-C 
rich regions and may occur more often following negative supercoiling from 
transcription. R-loops span anywhere from 100-2000 bp (base pairs) and can form 
within their own gene locus or binding to similar sequences distant from their origin 89,90. 
R-loops can be both activating or repressive, depending on where they form within a 
gene 91,92. R-loops formed around promoters or transcription start sites tend to increase 
adjacent gene transcription and are associated with hyperacetylation. R-loops formed 
around a transcriptional termination site are typically repressive by virtue of formation of 
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repressive histone methylation marks that may result in displacement of RNA pol II. 
Several lncRNAs have been found to form R-loops that either activate or repress gene 
transcription. VIM-AS1 is an antisense lncRNA, which forms an R-loop to activate the 
Vimentin gene 93. KHPS1 lncRNA also forms an R-loop to activate SPHK1, a proto-
oncogene related to renal cancer 94. MEG3 is another lncRNA, which forms an R-loop, 
but it represses factors that regulate the cytokine TGF-𝛃 in macrophages 95. The study 
of R-loop formation by lncRNAs is still in its infancy but may shed light on new functions 
or contribute further insight into the ways that lncRNAs can guide multiple binding 
partners to DNA.  
LncRNAs can perform a significant role in cell development and lineage 
commitment in the human body. LncRNAs are expressed in a more cell type specific 
manner than mRNAs 96. Cell type specific expression has implicated numerous 
lncRNAs in regulating and maintaining cell identity. Xist, one of the first regulatory 
noncoding RNAs ever identified, plays a key role in X chromosome dosage 
compensation during early embryogenesis 97-99. Xist RNA transcripts coat the surface of 
one X chromosome in somatic cells to recruit protein complexes to repress transcription 
across the X chromosome, which is sustained throughout the entire lifetime of somatic 
cells 99 .Another lncRNA, Braveheart (BVHRT), is necessary for effective development 
nascent mesoderm to a cardiac fate 100. BVHRT forms a stem loop structure to recruit 
chromatin modifying complexes and is necessary for transcription of MesP1. 
Cardiomyocytes cannot reach terminal cell fate when BVHRT is abrogated. Mutations 
and dysregulation of these lncRNAs have been implicated in disease. Loss of Xist 
results in re-expression of genes on the X-chromosome101-102.   
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The overexpression of X-linked genes is prevalent in female lymphocytes from lupus 
patients and in mouse models of autoimmunity 102. Multiple single nucleotide 
polymorphisms (SNPs) located within BVHRT have been implicated in an increased 
susceptibility to myocardial infarction.  
Thousands of unique lncRNAs have been identified expressed by CD4+ T-cells 
at different stages of development and differentiation thanks to RNA sequencing efforts. 
The cellular diversity of the immune system is matched by its lncRNA diversity. IFNG-
AS1, an antisense lncRNA located in the IFNG gene locus, is expressed by NK cells, 
CD8+, and CD4+ T-cells 103. IFNG-AS1 is induced by STAT4 and T-bet dependent 
pathways and interacts with T-bet to stimulate IFNG transcription during early TH1 
differentiation 104,105. Like previous examples, IFNG-AS1 also interacts with WDR5 to 
recruit and modify chromatin modifications in the IFNG gene locus. Linc-MAF-4 has also 
Figure 1-4. Model of R-Loop Formation. Following standard transcription, an RNA 
is normally trafficked away from its gene locus to be further processed as shown on 
the left. Sometimes, typically in a G-C rich region, it stays bound within its own locus 
forming a DNA:RNA hybrid, also known as an R-Loop as shown on the right. 
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been identified in TH1 cells 115. MAF, the mRNA partner, is expressed in polarized TH2 
cells and promotes expression of TH2 cytokine genes. Linc-MAF-4 recruits the 
repressive LSD1-EZH2 complex to repress the MAF gene in TH1 polarized cells 116. 
Linc-Maf-4 knockdown in non-polarized T-cells leads to Gata3 and IL-4 expression. 
Exogenous linc-MAF-4 transcripts repress TH2 cytokine gene expression, 
demonstrating a key role for this lncRNA in TH1 polarization.  
Locus control regions or LCRs are genomic enhancers that stimulate expression 
of linked genes that are members of a gene family, such as the globin genes or the 
growth hormone genes.  The IL4, IL5, and IL13 genes are also syntenic in vertebrate 
genomes and considered a gene family.  In mice, expression of TH2 cytokine genes is 
dependent upon a genomic enhancer region termed the TH2 locus control region of 
TH2 LCR.  The TH2 LCR functions by producing a lncRNA, termed the TH2LCRR 117. 
TH2LCRR has at least 4 unique isoforms, but each shares a central conserved 
nucleotide sequence. The TH2LCRR binds and guides WDR5 to the TH2 cytokine locus 
resulting in addition of permissive H3K4 methylation marks to stimulate transcription. 
Depletion of all TH2LCRR isoforms substantially reduces expression of IL-4, IL-5, and 
IL-13, but abrogation of individual isoforms by RNA interference does not effectively 
deplete TH2 cytokine expression. These results suggest that a common function of 
LCRs may be to transcribe a lncRNA that regulates expression of each member of a 
linked gene family, such as the TH2 cytokine gene family. 
 Initial studies in TH17 cells have identified lncDDIT4, a lncRNA related to DNA-
damage inducible transcript 4 (DDIT4) 109. DDIT4 is a cytoplasmic protein, which inhibits 
mTORC1 activity. LncDDIT4 lncRNA knockdown results in reduced expression of 
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DDIT4 and increased expression of IL-17. Taken together, these results suggest that 
induction of the lncRNA, lncDDIT4, leads to increased expression of the DDIT4 protein 
that, in turn, inhibits the mTOR pathway resulting in decreased function of effector TH17 
cells.  Hundreds of additional lncRNAs have been identified that are preferentially 
expressed by TH1, TH2, and TH17 lineages but studies of individual functions of these 
lncRNAs are still limited. 
In the past decade, the use of next-generation sequencing has changed our 
perception that most of the human genome is composed of insignificant “junk” to an 
appreciation of the broad array of regulatory RNAs transcribed by vertebrate genomes 
LncRNAs represent one such1 class of novel regulators of gene transcription and cell 
differentiation. The cell-type specific nature of lncRNAs makes them ideal biomarkers 
for evaluating cell populations and disease states in autoimmune disorders and cancer. 
Although numerous lncRNAs have been identified, functional studies have proceeded 
more slowly. Evaluation of molecular and cellular functions of individual lncRNAs, 
including their binding partners, downstream effects, and secondary structure will 
provide greater insights into the role of lncRNAs in cell development.   
 
Super-Enhancers 
 Cell development and fate is dictated by variation in the expression of genes. Our 
understanding of the activation and repression of gene transcription has evolved 
immensely to include the histone code, transcription factor complexes, and functional 
RNAs. As our knowledge of new regulatory factors has grown, so has our 
understanding of conserved regulatory regions within the DNA sequence. The 
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interactions between enhancers and promoters represent some of the earliest studies of 
gene regulation and continue today. 
 Enhancers are DNA elements that increase the transcriptional output of a target 
gene. Enhancers regulate a gene by helping to recruit the protein complexes necessary 
for efficient transcription to the promoter region 110. Enhancers can regulate genes 
independent of orientation or distance to the target gene, even targeting genes on other 
chromosomes 111-113. Distal enhancers can reach and interact with their target gene 
through DNA looping to facilitate the binding of transcription factors and RNA 
polymerase II (RNA Pol II) to the target gene promoter 114,115. Active enhancers can be 
identified by their lack of nucleosomes, leaving exposed DNA available for binding by 
transcription factors 73,74. Nucleosomes are the central subunit of packaged DNA and 
include 8 histone proteins, made up of two tetramers, and 147 bp of DNA. When DNA is 
packaged within nucleosomes, it is much less accessible for protein binding, limiting 
transcription and replication. 
 Enhancers can be identified by multiple methods. DNase-1 is an endonuclease, 
which cleaves regions of open accessible DNA that lack nucleosomes. Active 
enhancers are hypersensitive to DNAse-1 cleavage thanks to exposed transcription 
factor binding sites 116. DNA sequencing technology is used to identify and map 
enhancers via DNase1. The histone proteins flanking enhancer regions provide further 
evidence thanks to unique protein modifications 73. The histones flanking active 
enhancer regions are typically modified with H3K27ac and H3K4me1, while inactive 
enhancers are bound by nucleosomes often modified with repressive methylation 
marks. More recently, a new technique called ATAC-seq (Assay for Transposase 
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accessible Chromatin Sequencing) has developed to measure exposed chromatin 110. 
ATAC-seq uses a Tn5 transposase to simultaneously fragment and tag portions of DNA 
free of nucleosomes, which are then amplified and sequenced. The advantage of 
ATAC-seq versus the DNase hypersensitivity method is the increased nucleotide 
resolution and efficiency of measurement. 
Although a single enhancer can activate the expression of a gene, high levels of 
cell type specific expression of genes are typically associated with enhancer rich 
regions of the genome. Genome regions particularly rich with multiple enhancers are 
termed super-enhancers 117,118. A super-enhancer is a combined group of enhancers 
typically within ~12.5kb of each other enriched with a higher volume of transcriptional 
coactivators, like Mediator (Med1), P300, and BRD4, when compared to typical 
enhancers 118,119 (Figure 1-5). P300 is an acetyltransferase which adds acetyl groups to 
surrounding histones. BRD4 and Med1 bind to those acetyl groups and recruit RNA Pol 
II to stimulate transcription 75,120,121. H3K27ac and H3K4me2/3 are similarly more 
concentrated around super-enhancers than typical enhancers 117-119. Super-enhancers 
tend to span larger regions than a typical enhancer, but total length of a super-enhancer 
region is variable and can range from 10 kb to 100 kb while the average length of a 
typical enhancer is about 1 kb. The defining features of a super-enhancer are the 
exceptionally high enrichment of transcriptional activators and chromatin marks, as 
identified by chromatin immunoprecipitation and whole genome DNA sequencing, ChIP-
seq (Chromatin Immunoprecipitation sequencing), and exceptionally high transcription 
of the target gene.  
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Super-enhancers can direct and maintain cell identity by regulating lineage-defining 
genes during cell development 122,123. Initially studied in ESCs, Klf4 and Esrrb are 
transcription factors which are necessary to maintain pluripotency 117. Klf4 and Esrrb are 
both regulated by an associated super-enhancer region. Additionally, most super-
enhancers identified in ESCs bind both transcription factors. However, super-enhancers 
are not limited to pluripotent ESCs. Transcription factors Foxo1 and Ebf1 are needed for 
B cells to develop beyond common lymphoid progenitors 117,124. Both transcription 
factors are regulated by super-enhancers, which are further enriched in pro B cells. In 
CD4+ T-cells, the master transcription factors T-bet, Gata3, ROR𝜸t, and Bcl6 are each 
regulated by a predicted super-enhancer in their respective lineage 123. Additionally, 
these transcription factors preferentially bind within super-enhancer regions linked to 
their respective target cytokine genes 123,125. Most lineage defining genes of CD4+ T-
cells, including transcription factors, cytokines, and cytokine receptors, have a predicted 
super-enhancer associated with their transcription during polarization. 
 Super-enhancers have been increasingly analyzed for their role in transcription 
and cell development, but we lack a complete understanding of functional differences 
between super-enhancers and typical enhancers. Super-enhancers are differentiated 
from typical enhancers by the concentration of transcription factors bound to the 
enhancer region, total levels of chromatin marks at the enhancer region, and the total 
length of the enhancer region as defined by Whyte et al 118,119. These predicted super-
enhancers tend to be located in the genome next to highly transcribed, lineage-specific 
genes. However, super-enhancers have not been shown to induce transcription more 
effectively than a typical enhancer, in-vitro, a key definition of an enhancer. Additional  
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Figure 1-5. Typical and Super-Enhancer Regulation. Transcription factor binding 
to enhancers results in recruitment of the Mediator complex, helping to attract the 
RNA Pol II complex to a gene specific promoter. Super-enhancers increase the 
concentration of factors, increasing transcription rate of the target gene locus.  
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research evaluating the unique functions of super-enhancers will allow for a more 
uniform definition separating super-enhancers from typical enhancers. 
 
Summary 
The following three chapters will examine the contributions of unique cell specific 
epigenetic factors to the expression of T-helper cell specific genes. These studies 
evaluate regulation primarily in T-helper polarized cells but extend to include memory T 
cells and NK cells. The first chapter examines the role of a divergent lncRNA, GATA3-
AS1, in the expression of Gata3 and the polarization of TH2 cells. GATA3-AS1 is 
necessary for effective TH2 polarization and regulates Gata3 expression by recruiting a 
chromatin modifying complex to remodel the GATA3 gene locus. The second chapter 
examines the methods for evaluating R-Loop formation within cells using the DRIP 
(DNA-RNA immunoprecipitation) assay with the S9.6 antibody. The final chapter 
demonstrates the necessary role of a super-enhancer in IFN-γ expression amongst 
multiple cell lineages. IFN-γ expression is reduced in all cells following treatment with 
the bromodomain inhibitor, JQ1, but expression is recovered after removing the 
treatment from TH1 cells. Our results suggest that bromodomain inhibitors may disrupt 
the function of both innate and adaptive arms of the immune response.  Bromodomain 
inhibitors are being developed for treatment of certain malignancies as well as 
inflammatory disease and our findings suggest that a consequence of bromodomain 
inhibitors as treatments for disease may be to inhibit the normal immune response.   
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CHAPTER II 
 
DIVERGENT LNCRNA GATA3-AS1 REGULATES GATA3 TRANSCRIPTION IN T-
HELPER 2 CELLS 
 
Abstract 
Long non-coding RNAs (lncRNAs) possess a diverse array of regulatory 
functions including activation and silencing of gene transcription, regulation of splicing, 
and coordinating epigenetic modifications. GATA3-AS1 is a divergent lncRNA gene 
neighboring GATA3. Gata3 is considered the master regulator of TH2 lineage 
commitment enabling TH2 effector cells to efficiently transcribe genes encoding 
cytokines IL-4, IL-5, and IL-13. Here, we show that the GATA3-AS1 lncRNA is 
selectively expressed under TH2 polarizing conditions and is necessary for efficient 
transcription of GATA3, IL5, and IL13 genes, while being sufficient to induce GATA3 
expression. GATA3-AS1 is required for formation of permissive chromatin marks, 
H3K27 acetylation and H3K4 di/tri-methylation, at the GATA3-AS1-GATA3 locus. 
Further, GATA3-AS1 binds components of the MLL methyltransferase and forms a 
DNA-RNA hybrid (R-loop) thus tethering the MLL methyltransferase to the gene locus. 
Our results indicate a novel regulatory function for a divergent lncRNA and provide new 
insight into the function of lncRNAs in T helper cell differentiation. 
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Introduction 
Long noncoding RNAs (lncRNAs) represent a new class of regulatory molecules 
impacting a vast array of biological functions.  LncRNAs are defined as >200 
nucleotides in length but possess little if any protein-coding potential 63. LncRNA genes 
are oftentimes named in reference to their neighboring protein-coding genes in the 
genome 126,127. Divergent lncRNAs represent one such class and divergent lncRNA 
gene transcriptional start sites are juxtaposed to their adjacent mRNA gene 
transcriptional start sites and may impact transcription of this mRNA by various 
mechanisms. Previous studies have implied that divergent lncRNAs may have no true 
function but transcription of the divergent lncRNA may make the gene locus more 
accessible or alternatively, compete for mRNA gene promoters or proximal enhancers 
126,128,129.LncRNAs may be localized to the cytoplasm or nucleus.  One common 
mechanism by which lncRNAs act is to recruit histone modifying machinery to gene loci 
and activate or repress transcription of target mRNA gene loci 103.  However, how 
lncRNAs find their target gene loci, which can be in cis or trans, is less well understood.  
One mechanism that has been described is via formation of DNA-RNA hybrids. An 
example is the lncRNA, VIM-AS1, which modifies its neighboring VIM gene by forming 
an R-loop 93. An R-loop can form via G-Rich RNA hybridization to a DNA sequence, 
forming an RNA: DNA hybrid.  
GATA3-AS1 represents one divergent lncRNA and shares a promoter region with 
GATA3. The Gata3 transcription factor is considered the master transcriptional regulator 
of T Helper 2 (TH2) lineage commitment 130 and is required for induction of IL4, IL5, and 
IL13, genes required for expression of sentinel TH2 cytokines 131. GATA3-AS1 levels 
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are elevated in human TH2 cells compared to other T helper cell subsets 117. 
Expression of GATA3-AS1 is also increased in response to allergen stimulation in 
patients with allergy or asthma suggesting GATA3-AS1 may contribute to disease 
pathogenesis 132. 
In this study, we show GATA3-AS1 is necessary for efficient transcription of 
Gata3 as well as IL5 and IL13 genes. GATA3-AS1 both binds to the MLL H3K4 
methyltransferase and forms an R-Loop within its own locus to facilitate chromatin 
remodeling within the GATA3-GATA3-AS1 locus.  
 
Materials and Methods 
Cell Culture, RNA Isolation and Quantitative RT-PCR. Human peripheral 
blood mononuclear cells (PBMC) were cultured under TH0, TH1, TH2, and TH17 
polarizing conditions as previously described 117. Cultures were harvested after 5 (TH1, 
TH2) or 7 days (TH17).  Cultures were also re-stimulated with anti-CD3 for 2 days for 
analysis of effector cells (TH1-E, etc.).  Total RNA isolation, cDNA synthesis using poly-
A selection and analysis by quantitative PCR (qPCR) was performed as previously 
described 117.  Expression levels of target transcripts were normalized to levels of 
GAPDH using the formula 2(GAPDH Ct-target gene Ct). Primer Pairs used in qPCR 
reactions are listed in Supplementary Table 1. The study was approved by the 
institutional review board at Vanderbilt University Medical Center. Written informed 
consent was obtained at the time of blood sample collection. 
Cell Fractionation Assay. Human PBMC were incubated to produce TH2 
primary and effector populations. Cytoplasmic and nuclear fractions were isolated using 
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a PARIS kit (AM1921, ThermoFisher). RNA from each fraction was isolated as 
described above. 
RNAi Transfections. Human PBMC were incubated for a total of 5 days under 
TH2-polarizing conditions. Cells were transfected after 2d of culture with Lipofectamine 
RNAiMax (Life Technologies) using either an inventoried Silencer Select negative 
control siRNA or custom designed Silencer Select siRNA for GATA3-AS1 (DesignID: 
AD0IWKB and AD1RUQJ), or GATA3 (DesignID: AD6RNGV amd AD5IPAN) per 
supplied protocols. Cells were harvested after 5 days and used for either RNA analysis 
via qPCR, ChIP analysis, ELISA, and Western Blot 
Enzyme Linked Immunosorbent Assay (ELISA). Elisa assays were performed 
according to instructions provided by the kits to analyze IL-4 (555194,BD Biosci), IL-5 
(555202, BD Biosci), IL-13 (88-7439-88, Invitrogen), and IFN-γ (555142, BD Biosci) 
proteins. Cultures were performed as described under RNAi transfections.  Cultures 
were harvested and analyzed by ELISA. 
Western Blot. Cells were lysed with RIPA buffer supplemented with protease 
inhibitors (cOmplete Mini, Roche) and phosphatase inhibitors (PhosStop inhibitor 
cocktail, Roche). Protein concentration of each sample was determined by Pierce BCA 
Protein Assay kit. Lysates were subjected to SDS/PAGE followed by blotting with the 
indicated antibodies. Signal was detected using the IR-dye conjugated secondary 
antibodies and the Odyssey scanner (Li-cor Biosciences). Antibodies against the 
following proteins were used: GATA3 (#199428, Abcam) and β-Actin (#47778, Santa 
Cruz).   
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In-Vitro Transcription. Full length GATA3-AS1 was generated by PCR 
amplification, agarose gel purified using a QIAquick gel extraction kit (28704, QIAGEN) 
and cloned into a TOPO-TA dual promoter transcription vector (K462001, 
ThermoFishter). Clone identify was verified by digestion of plasmids with Spe1 
(R0133S, NEB) and Not1 (R0189S, NEB), and DNA sequencing via GENEWIZ.   
GATA3-AS1 transcripts were produced via the T7 promoter using the maxiscript T7 
transcription kit (AM1312, ThermoFisher). Full length transcripts were transfected into 
TH0 cells at day 2, at concentrations of 0.5 uM and 0.1 uM similar to RNAi 
transfections. 
Chromatin immunoprecipitation (ChIP). ChIP procedures were as previously 
described 117 using an anti-H3K4me2/3 (ab6000, Abcam), anti-H3K27ac (ab4729, 
Abcam), or anti-mouse IgG (sc-2025, SantaCruz Biotech). DNA was isolated from 
beads via phenol chloroform extraction and purified using QiaQuick PCR purification 
kits. Isolated chromatin was analyzed using SYBR-Green qPCR (Applied Biosystems). 
Values were expressed as fraction of total input from chromatin samples.  
RNA-immunoprecipitation (RIP). RIP assays were performed as described 
previously 117. Briefly, TH2 primary cultures were harvested, lysed, and chromatin 
sheared by sonication followed by incubation with an isotype IgG control antibody 
(sc2025, SantaCruz Biotech), anti-WDR5 (ab56919, Abcam), or anti-p300 (ab14984, 
Abcam) overnight at 4°C. Protein A/G beads (sc2003, SantaCruz Biotech) were added 
to lysates and incubated at 4°C for an additional 4 hours. Beads were pelleted, 
supernatants harvested, and beads were washed and suspended in Tri-Reagent. RNA 
was isolated and analyzed via qRT-PCR as described above.  
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DNA-RNA Hybrid Immunoprecipitation (DRIP). DRIP assays were performed 
as described 133 using the track 17 in development of protocol. Briefly, TH2 primary 
cultures were harvested, lysed, and chromatin sonicated at 2x10 min (medium, 
Diagenode Bioruptor) to yield an average chromatin size of ~500 bp. Samples were 
treated with proteinase K at 65°C overnight. Total nucleic acid was isolated by phenol 
chloroform extraction. Six micrograms of nucleic acid was rotated overnight with S9.6 
antibody followed by incubation with protein A/G beads (SantaCruz Biotech) for 4 hours. 
Beads were subsequently washed 4 times followed by isolation via Tri-Reagent for RNA 
or phenol chloroform extraction for DNA. Samples were analyzed by qPCR as 
described above. 
 
Results 
Selective expression of GATA3-AS1 by TH2 populations. Genes encoding 
GATA3-AS1 and GATA3 are adjacent to each other on human chromosome 10 (Figure 
2-1A).  GATA3 is transcribed in the sense orientation and GATA3-AS1, the antisense 
orientation.  Transcriptional start sites for GATA3 and GATA3-AS1 are separated by 
~1200 bp. Thus, GATA3 and GATA3-AS1 belong to the general class of divergent 
lncRNA/mRNA pairs. At least six GATA3-AS1 splice variants have been identified that 
utilize four major exons. Whole genome RNA-sequencing confirmed multiple regions 
were transcribed in primary (upper panel) and effector (lower panel) TH2 cultures 
(Figure 2-1B). Each exon and intron region of GATA3-AS1 was evaluated in TH2 
primary cells with targeted primer pairs to analyze total expression at these sites.  
 30 
 
Figure 2-1. GATA3-AS1 is expressed in TH2 cells. (A) Genomic locations of 
human GATA3-AS1 known isoforms and GATA3 with directions of transcription in sense (>) 
and antisense orientations (<) from UCSC genome browser (hg19 build). (B) Whole genome 
RNA-seq tracks of GATA3-AS1 expression in primary (upper) and effector (lower) TH2 cells, 
Y-axis is in FPKM. Approximate composition of GATA3-AS1 transcripts in TH2 primary cells 
was verified by PCR. Arrows indicate approximate genomic locations of seven PCR primer 
pairs used for the analysis. Numbers below the arrows represent relative transcript amounts 
at each primer location, and are expressed relative to the highest expressed region. Also 
depicted as a bar graph above the arrows. (C) PCR primer pair locations used to measure 
exons 1-4 designated as regions 1-4, respectively. Expression levels of GATA3-AS1 regions 
1–4 in TH1, TH1-E, TH2, and TH2-E, subsets. Results are expressed relative to levels 
of GAPDH (n = 3), Statistical significance vs. TH1 effector cells was determined by 
Students T-test. *P < 0.05. 
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GATA3-AS1 transcripts contained the four predicted exons, as well as the most 
downstream intron (Figure 2-1B). The first and second predicted introns were not 
present. We decided to examine the four predicted exons, designated regions 1-4, to 
determine their expression levels in T helper cell cultures. We found that regions 1-4 
were selectively expressed in primary and effector TH2 cultures relative to primary and 
effector TH1 cultures (Figure 2-1C). Regions 3 and 4 exhibited higher expression levels 
than regions 1 and 2 consistent with our RNA-sequencing results. We subsequently 
searched for TH2-specific noncoding RNAs in the mouse genome around Gata3. We 
examined published RNA-seq data 134 and identified three lncRNA genes in the vicinity 
of Gata3 selectively expressed in TH2 cultures relative to TH1 and TH17 cultures. 
These were 103 kb, 290 kb, and 336 kb, respectively, 3’ of Gata3, named lincR-Gata3-
3’S-336K (S=transcribed in sense direction relative to Gata3), lincR-Gata3-3’S-290K, 
and lincR-Gata3-3’.  Given their genomic distances from Gata3, these did not fall into 
the general divergent lncRNA class. 
LncRNAs may function in the nucleus or cytoplasm 135. Therefore, we asked if 
GATA3-AS1 existed primarily in nuclear or cytoplasmic compartments of TH2 cells. We 
isolated nuclear and cytoplasmic fractions, isolated total RNA from each fraction and 
evaluated GATA3-AS1 levels by PCR. HPRT was used as a cytoplasmic specific 
control mRNA, while VIM-AS1 represented our nuclear specific control 93. We found that 
GATA3-AS1 was located primarily within the nuclear fraction (Figure 2-2A). We 
compared the kinetics of induction of GATA3-AS1 under TH2 polarizing conditions to 
induction of GATA3, IL4, IL5, and IL13 (Figure 2-2B, 2-2C).  We found a continual  
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Figure 2-2. GATA3-AS1 is localized in the nucleus and expression increases during 
TH2 cell polarization. (A) Cellular and nuclear fractions of primary and effector TH2 
populations analyzed via qPCR. Values represent ΔΔCT vs. whole cell GAPDH. VIM-
AS1 lncRNA is a nuclear control, while HPRT mRNA represents a cytoplasm specific 
control. Statistical significance vs. relative cytoplasmic fraction was determined by Students 
T-test (n = 3). *P < 0.05 (B) Total PBMCs were cultured under TH1 or TH2 polarizing 
conditions, and RNA was isolated on consecutive days. Mean ± S.D. gene transcripts 
of GATA3-AS1 were quantified via qPCR and normalized to GAPDH. (C) Similar analyses 
were completed for GATA3, IL4, IL5, and IL13. Statistical significance vs. TH1 effector cells 
on day 7 was determined by Students T-test (n = 3). *P < 0.05. 
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increase in expression of GATA3, IL4, IL5, and IL13 over time.  GATA3-AS1 displayed 
a similar increase in transcript levels as a function of time after stimulation. Thus, 
GATA3-AS1 induction paralleled induction of genes known to mark the TH2 
differentiation pathway. 
Depletion of GATA3-AS1 disrupts induction of GATA3, IL13 and IL5 genes. 
To further explore possible functions of GATA3-AS1, we designed an siRNA to target 
the most highly expressed region of the lncRNA, region 4. Total human PBMCs were 
cultured under TH2 conditions and the GATA3-AS1 specific siRNA was transfected into 
cells on day 2. A scrambled siRNA with nonspecific target was used as a negative 
control. Total RNA was isolated on day 5 when cells reached primary stage. We found 
that GATA3-AS1 regions 2, 3, and 4 were significantly reduced after transfection 
compared to transfection with the scrambled control siRNA (Figure 2-3A).  Transfection 
with the GATA3-AS1 specific siRNA also led to a marked reduction in GATA3, IL13, and 
IL5 mRNAs. GATA3-AS1 reduction similarly reduced protein levels of IL-5, IL-13, 
(Figure 2-3B) and Gata3 (Figure 2-3C). IFN-γ production was not significantly impacted 
by transfection in TH1 cells, showing minimal off target effects. This demonstrates the 
GATA3-AS1 transcript is required for effective induction of major TH2 genes. In 
contrast, IL4 showed increased transcript levels following the lncRNA knockdown. This 
is consistent with previous studies showing that knockdown of GATA3 may induce 
compensatory effects resulting from increased STAT6 binding to the IL4 locus 31. 
Alternatively, more complete depletion of GATA3 may be required to abrogate IL4 
induction in this model system.  Taken together, these results demonstrate that GATA3-
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AS1 plays an important role in GATA3 induction during initial primary TH2 
differentiation.  Our interpretation is that depletion of GATA3-AS1 results in loss of  
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induction of GATA3 under TH2 differentiation conditions leading to reduced IL-13 and 
IL-5 expression.   
Despite expanding literature on lncRNAs, impact of the mRNA partner on 
transcription of a divergent lncRNA is not well understood.  Gata3 induction creates a 
positive feedback loop, by binding to its own promoter region 136,137. Because of the 
shared promoter region, Gata3 protein binding may impact the expression of GATA3-
AS1 during polarization. To test this hypothesis, we decreased GATA3 levels via siRNA 
knockdown to evaluate its impact on the expression of GATA3-AS1 (Figure 2-3D). 
GATA3-AS1 showed a significant reduction following GATA3 depletion, indicating 
Figure 2-3. GATA3-AS1 and GATA3 form a necessary feed forward loop regulating 
TH2 polarization. (Previous Page) (A) PBMCs were cultured under TH2 polarizing 
conditions for 2 days and transfected with a GATA3-AS1 specific siRNA (+) or scrambled 
siRNA (–). GATA3-AS1, GATA3, IL4, IL5, and IL13 transcripts were determined by qPCR on 
day 5 and results expressed relative to GAPDH. Statistical significance was determined 
using Students T-test by comparing GATA3-AS1 siRNA knockdown to scrambled control 
knockdown (n = 3). *P < 0.05 (B) PBMCs were cultured under TH2 or TH1 polarizing 
conditions and transfected with GATA3-AS1 specific siRNA (+) or scrambled siRNA (–). 
Protein was analyzed by ELISA (for IL-4, IL-5, and IL-13, n = 3,) or (C) Western Blot 
(GATA3, Densitometry). Statistics were calculated using a Paired T-test compared negative 
siRNA controls. *P < 0.05. (D) Similar to A, but an siRNA specific to GATA3 was transfected 
on day 2. Results and statistics similar to A, but (n = 4). (E) PBMCs were cultured under TH0 
conditions for 2 days, and transfected with GATA3-AS1 transcripts produced from Topo-
TA in-vitro transcription vector. Cells were transfected with a scrambled siRNA (negative), 
the antisense of GATA3-AS1(antisense), GATA3-AS1 at 500 μM (AS1 High), and GATA3-
AS1 at 100 μM (AS1 Low). Analysis and statistics completed similarly to A and B, (n = 5). 
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GATA3 is also required for effective GATA3-AS1 expression. Thus, GATA3-AS1 is 
necessary for effective induction of GATA3, while GATA3 subsequently increases 
GATA3-AS1 transcript levels creating a kind of feed-forward loop.  
Above results demonstrated that siRNA-mediated knockdown of GATA3-AS1 
reduced GATA3 induction under TH2 polarizing conditions.  Therefore, we asked if 
elevated GATA3-AS1 was sufficient to induce GATA3 expression.  We used a Topo-TA 
cloning vector to produce full length transcripts of GATA3-AS1 and verified the product 
via sequencing. We transfected GATA3-AS1 into TH0 cells at two different 
concentrations (0.5 and 0.1 μM) and analyzed GATA3 and genes encoding TH2 
cytokines. We found GATA3 transcript levels were significantly higher following 
transfection of GATA3-AS1, but this transfection did not induce genes encoding TH2 
cytokines (Figure 2-3E). Thus, GATA3-AS1 is sufficient to increase GATA3 in non-
polarized T-cells, further demonstrating that regulation GATA3 via GATA3-AS1 is 
dependent on the RNA transcript, not on the act of its transcription.  
GATA3-AS1 binds and recruits MLL methyltransferase via WDR5. Several 
lncRNAs localized in the nucleus can modify transcription of target genes by impacting 
the state of chromatin in the region 138. This can be achieved by facilitating binding of 
large histone modifying complexes to chromatin and/or direct interaction with DNA 83. 
To investigate the effect of GATA3-AS1 on chromatin marks, we performed the 
knockdown of GATA3-AS1 as described above and isolated chromatin from TH2 
primary cells on day 5. We processed chromatin for ChIP assays and performed 
immunoprecipitations with antibodies specific for either H3K27ac or H3K4me2/3 marks.  
We designed a series of PCR primer pairs to interrogate genomic regions across 
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GATA3-AS1 and GATA3 genes (Figure 2-4A).  Following knockdown of GATA3-AS1 via 
siRNA transfection, we found significantly decreased H3K27ac and H3K4me2/3 
activating marks across GATA3-AS1 and GATA3 genomic regions including the shared 
promoter (Chip 3-5), GATA3-AS1 introns and GATA3 introns (Figure 2-4B, 2-4C). The 
variation in chromatin marks was not present in chip primers 9 and 10, located after the 
second exon of the GATA3 gene. These results indicate that GATA3-AS1 is required for 
adequate addition of H3K27ac and H3K42/3me marks to both its own gene locus, the 
shared promoter region and the GATA3 locus. 
Previous studies have demonstrated that one mechanism that lncRNAs can alter the 
epigenetic code is by binding to chromatin modifying complexes to facilitate their 
recruitment to target genomic loci 139. An example is the MLL H3K4-methyltransferase 
complex of which WDR5 is an essential component 140. To investigate this possible 
interaction, we performed RNA immunoprecipitations using antibodies specific for 
WDR5.  We isolated RNA from the immunoprecipitates and analyzed recovery of 
GATA3-AS1 transcripts via qPCR. We found that a significantly higher portion of 
GATA3-AS1 regions 3 and 4 were immunoprecipitated with antibodies to the WDR5 
protein than the pan-hnRNP negative control antibody or an isotype control (Figure 2-
4D).  We performed a similar immunoprecipitation using antibodies to p300. p300 is one 
chromatin modifying enzyme responsible for formation of H3K27ac marks 141. Unlike the 
MLL methyltransferase, there was no detectable interaction between GATA3-AS1 and 
the p300 complex in TH2 cells (Figure 2-4E). These results demonstrate GATA3-AS1 
binds the MLL H3K4-methyltransferase complex via interactions involving primarily 
region 4.   
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GATA3-AS1 forms an R-Loop. An R-loop is the formation of a DNA:RNA:DNA 
triplex, in which an RNA binds within its own gene region, instead of being released  
 39 
  
Figure 2-4. Expression of GATA3-AS1 changes chromatin marks throughout 
the GATA3-AS1-GATA3 gene locus. TH2 cultures were transfected with an siRNA specific 
for GATA3-AS1 region 4 or a scrambled control siRNA on day 2 as described in Figure 2-3. 
Cultures were harvested and processed for ChIP assays on day 5. Results are expressed as 
fraction of input, mean ± S.D. (n = 3). *P < 0.05. (A) Approximate genomic positions of PCR 
primers used for ChIP assays. (B) ChIP assays for H3K27ac. (C) ChIP asays for 
H3K4me3. (D) WDR5 was immunoprecipitated from TH2 effector whole cell lysates. RNA 
was isolated from immunoprecipitated WDR5, and GATA3-AS1 regions 1–4 determined by 
qPCR. Results are expressed as fold enrichment relative to isotype control, mean ± S.D. (n = 
3). *P < 0.05. (E) As in (D), except an antibody to p300 was employed for RNA 
immunoprecipitation. 
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following polymerase activity as normally occurs. R-loops, when formed at the 
transcriptional start site may produce an open gene region to promote transcription 142.  
R-Loops typically form within a region of high G-C skew.  In a recent study 93, VIM-AS1 
was found to form an R-loop within the VIM gene region.  Using the recently developed 
R-loop database 143, we searched the GATA3-AS1 and GATA3 genomic locus and 
identified the intron between regions 2-3 of GATA3-AS1 as having a high probability of 
forming an R-Loop because of the high relative G-C skew throughout the region (Figure 
2-5A). We predicted that formation of an R-Loop may help tether the lncRNA to this 
region, and to test this hypothesis, we performed a DNA-RNA immunoprecipitation 
assay (DRIP). The DRIP assay follows a standard ChIP assay protocol, but uses the 
S9.6 antibody, specific for RNA-DNA hybrid structures 133. The DRIP assay allows for 
analysis of both the bound RNA transcript, as well as the region of DNA to which it has 
bound. The RNA typically stays localized to its own gene locus, but the formation of the 
R-Loop at the transcription start site or the termination site indicates different regulatory 
functions. We completed the DRIP and isolated RNA samples from immunoprecipitates 
and found that all four regions of the GATA3-AS1 lncRNA were enriched in the 
immunoprecipitates (Figure 2-5B).  Regions 1, 2, and 3 were significantly enriched 
compared to the GAPDH control similar in magnitude to the VIM-AS1 positive control.  
We performed a similar immunoprecipitation but isolated the DNA fraction via phenol 
chloroform extraction. We detected R-Loop formation in an RNase H dependent manner 
located within the G-C rich central intron of GATA3-AS1 (Figure 2-5C). These results, 
taken together, indicate that GATA3-AS1 binds the DNA region within the central intron  
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Figure 2-5. GATA3-AS1 RNA forms an R-Loop with the central intron of GATA3-
AS1. (A) Predictive R-Loop formations according to the R-Loop database. The largest and 
most likely R-Loop is circled, located between regions 2 and 3 of GATA3-AS1. (B) DRIP 
assay completed with RNA isolation. Results are expressed as fold enrichment relative to the 
RNase H negative control. Chromatin was treated with RNase to remove R-Loops as an 
additional control, mean ± S.D. (n = 3). *P < 0.05. (C) DRIP assay similar to (B), but DNA 
was isolated from the R-Loop immunoprecipitates. PRO1 and 2 represent the shared 
promoter region, INT is the central intron of GATA3-AS1, and Post3' is past the GATA3-
AS1transcriptional end site. Statistical evaluations were performed using Students t-test vs. 
Rnase H negative control. All data represent mean± S.D. as fraction of input (n = 4). *P < 
0.05. 
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of GATA3-AS1 and could represent a mechanism by which the divergent lncRNA is 
able to recruit chromatin modifying complexes to the GATA3 gene locus. 
 
Discussion 
 We show that the lncRNA, GATA3-AS1, is selectively expressed under 
TH2 differentiation conditions, is primarily localized to the nucleus and is necessary for 
efficient expression of GATA3 during TH2 lineage commitment and expression of IL5 
and IL13, genes encoding cytokines critical for TH2 cell function.  Further, GATA3-AS1 
lncRNA is sufficient to induce GATA3 expression further indicating this divergent 
lncRNA has biologic function, though it cannot induce total TH2 polarization 
independent of other factors such as c-Maf or STAT6. GATA3-AS1 is necessary for 
chromatin remodeling at the GATA3-AS1-GATA3 locus. Chromatin modifications are 
accomplished by the ability of GATA3-AS1 RNA transcripts to specifically bind the MLL 
H3K4-methyltransferase complex and tether it to the GATA3-AS1-GATA3 locus. 
GATA3-AS1 also forms a DNA-RNA hybrid within the GATA3/GATA3-AS1 locus, 
termed an R loop suggesting one mechanism by which GATA3-AS1 may recruit the 
MLL H3K4-methyltransferase complex to the locus. 
In addition to GATA3-AS1, lncRNAs are involved in additional aspects of TH cell 
differentiation and function.  For example, the lncRNA, TH2LCRR, is selectively 
transcribed from the TH2 locus control region (LCR) in developing TH2 cells, binds the 
MLL H3K4-methyltransferase complex, is necessary for chromatin remodeling at IL4, 
IL5 and IL13 genomic loci and induction of IL4, IL5, and IL13 genes in response to TH2 
lineage commitment 117. It is not known if TH2LCRR forms a DNA-RNA hybrid as 
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described here but this seems possible.  The lncRNA, LincR-Ccr2-5’AS, is induced 
under TH2 polarizing conditions and regulates induction of genes encoding chemokine 
receptors, including Ccr2, as well as TH2 cell migration, in vivo 134.  In contrast to 
GATA3-AS1 and TH2LCRR, its mechanism of action is not known but this lncRNA does 
not seem to contribute to chromatin remodeling at these gene loci.  IFNG-AS1 
(Tmevpg1, NeST) is critical for IFNG expression during TH1 lineage commitment, by T 
effector memory cells, and in-vivo 103-105,144. The lncRNA, Rmrp, plays an important role 
in TH17 lineage commitment by regulating interactions between Ror-γt and its RNA 
helicase DEAD-box protein 5 (DDX5) binding partner 145.  Thus, lncRNAs regulate many 
facets of TH cell differentiation and function, and GATA3-AS1 significantly contributes to 
TH2 development.  
GATA3-AS1 can be considered one member of the class of divergent lncRNAs in 
which the transcriptional start site of the lncRNA gene is very close (~100-1000 bp) to 
the transcriptional start site of the adjacent mRNA gene.  In this case, it has not been 
clear if the lncRNA actually has a function.  It has been proposed that these divergent 
lncRNA/mRNA pairs may share common promoters or proximal enhancers and that 
competition may impact gene expression rather than the RNA that is produced from the 
divergent lncRNA gene. Alternatively, the very act of transcription of the lncRNA gene 
may facilitate chromatin remodeling to alter transcription of the neighboring mRNA 
gene.  Our results are consistent with the interpretation that the GATA3-AS1 lncRNA, as 
opposed to these other proposed mechanisms, is necessary for the adequate 
transcription of GATA3. Importantly, the GATA3-AS1 transcript alone is sufficient to 
induce an increase in GATA3 expression. These results are unique among divergent 
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lncRNAs and show the noncoding RNA molecule as an essential feature of its 
regulatory capacity. Despite the increase in GATA3 following GATA3-AS1 transfection, 
GATA3-AS1 transcripts alone could not induce TH2 polarization. Other factors, like 
STAT6 and c-MAF, also involved in TH2 polarization, may also be necessary. 
Formation of RNA-DNA hybrids or R-loops are common, and R-loops are 
prevalent along chromosomes impacting many cellular processes 142.  Similarly, one 
mechanism by which lncRNAs are thought to act is by recruiting histone modifying 
enzymes to target gene loci. However, except in a few instances 146, it has not been 
entirely clear how these lncRNA-enzyme complexes find their target gene loci. The 
formation of an R-Loop by GATA3-AS1 may allow the effective recruitment of chromatin 
modifying enzymes to the GATA3-AS1-GATA3 locus, but further experiments will be 
necessary to demonstrate this relationship. R-loop formation may represent a general 
mechanism employed by lncRNAs to find their target gene loci or may be unique to 
divergent lncRNA/mRNA gene pairs that exist in close proximity in the genome. 
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CHAPTER III 
 
IMMUNOPRECIPITATION OF DNA-RNA HYBRIDS USING THE S9.6 ANTIBODY 
 
Abstract 
Formation of DNA:RNA hybrids or R-loops contribute to numerous biologic 
processes. Development of the S9.6 antibody makes analysis of R-Loops (DNA:RNA 
hybrids) possible through immunoprecipitation.  Here we describe the isolation of 
DNA:RNA hybrid structures through the use of the S9.6 antibody.  Using this protocol, 
both the DNA and RNA binding partners of the R-loop can be analyzed via qPCR, 
whole genome sequencing or other methods. 
 
Introduction 
DNA:RNA hybrids (or R-loops) are important regulators of transcription and 
impact processing at initiation, elongation, and termination 90,91,93,133,147,148.  R-loops are 
triple stranded nucleic acid structures including a DNA:RNA hybrid strand and one 
displaced DNA strand 149.  R–loops can regulate transcription by blocking transcriptional 
silencing by preventing binding of DNA methyltransferases and subsequent DNA 
methylation of CpG islands 89, induce transcriptional termination by RNA polymerase 
pausing 150, and repress transcription by promoter occlusion4. Ranging in size from 50-
2000 bp, R-loops are abundant around promoters and modify transcription to both 
induce and repress impacted genes 151. Antisense and divergent long noncoding RNAs 
can also form R-loops to regulate transcription of neighboring mRNA genes 93,152. R-
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loops can also cause replicative stress 153, genome instability 151, and chromatin 
alterations that may be associated with cancer 150,154. Effective analysis of R-loop 
formation and location is critical to understand transcriptional dynamics.  
R-loops were previously studied using a variety of techniques including mobility 
shift assays, in situ hybridization, and native bisulfite modification. Analysis of R-loops 
greatly expanded following the development of the of the S9.6 antibody that specifically 
recognizes these DNA:RNA hybrids 155.  The S9.6 antibody binds to DNA:RNA hybrids 
in a sequence independent manner, making immunoprecipitation of the R-loop 
(DNA:RNA immunoprecipitation or DRIP) a standard detection method 156.  The DRIP 
technique, first introduced in 2010, made analysis of R-loops more accessible and 
comprehensive through qPCR analysis and whole genome sequencing 92. The DRIP 
technique does have limitations. The S9.6 antibody binds double stranded RNA, though 
not as effectively as it binds DNA:RNA hybrids 91. Additionally, formaldehyde 
crosslinking can increase the number of false positives detected 157. Despite this, the 
DRIP assay is still by far the most effective tool to analyze R-loop locations and size. 
Here we describe an immunoprecipitation procedure to analyze both the DNA 
and RNA fractions involved in R-Loop formation (Figure 3-1). In this protocol, cells are 
fixed with formaldehyde, lysed, and sonicated similar to a standard ChIP assay. R-loops 
are immunoprecipitated using the S9.6 antibody, followed by extraction of either the 
RNA or DNA fraction from the immunoprecipitate. DNA or RNA fractions can be 
analyzed via qPCR or sequencing to provide effective analysis of R-loop formation 
around a single gene or throughout the entire genome.  
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Materials and Methods 
*Carry out all methods with samples on ice unless otherwise specified  
Fixation 
1. Using no more than 10 million cells, add formaldehyde directly to the media, dropwise 
to a final concentration of 0.75% of total volume, and rotate for 10 minutes. (Example: 
a 3 ml culture would receive 60.8 μl of formaldehyde). 
2. Add glycine to a final concentration of 125 mM to the media, and rotate again for 5 
minutes at room temperature. 
3. Isolate cells by centrifuging at 4°C and 300 x g for 10 minutes. 
4. Pour off the supernatant from the sample. 
5. Wash once in ice cold PBS at an equivalent volume to the previous media volume. 
6. Repeat step 3 and remove as much PBS as possible without disturbing the cell pellet 
(See Note 3). 
Nuclei Isolation 
Materials Used 
• Hypotonic solution: 20 mM Tris-HCl, pH 7.4, 10 mM NaCl, 3 mM 
MgCl210% NP-40 
• R-Loop Digestion Buffer: 100 mM NaCl, 10 mM Tris pH 8, 25 mM EDTA 
pH 8, 0.5% SDS, 0.2 mg/ml Proteinase K (add just prior to use) (See Note 
1) 
• FA Lysis Buffer: 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM Na2EDTA, 
1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM β-
glycerophosphate, 1 mM Na3VO4, 1 μg/ml leupeptin (See Note 2) 
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Figure 3-1. DNA:RNA immunoprecipitation protocol flowchart. Each step is uniform until 
after the S9.6 antibody immunoprecipitation, in which the DNA and RNA fractions are 
processed separately so both can be isolated from the immunoprecipitated. 
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1. Resuspend cell pellet in 500 μl of Hypotonic Solution and pipette up and down to mix.  
2. Incubate for 15 minutes. 
3. Add 25 μl of 10% NP40 detergent and vortex on highest setting for 10 seconds. 
4. Centrifuge at 4°C at 720 x g for 10 minutes. 
5. A pellet should be visible at the bottom of the tube containing cell nuclei. Remove the 
supernatant from the tube without disturbing the pellet. 
6. Resuspend pellet in 1 ml of R-Loop Digestion Buffer and leave overnight in a 65°C 
water bath (approx. 12-16 hours). Remove samples from the water bath, and 
immediately place on ice.  
7. Add 500 μl of 25:24:1 Phenol:Chloroform:Isoamyl Alcohol to the sample, pipetting up 
and down to mix effectively.  
8. Centrifuge sample at 4°C at maximum speed (~21,000 x g) for 10 minutes. 
9. Isolate the top aqueous layer, which will contain the nucleic acids from the sample.  
10. Combine aqueous layer with ¼ volume of 9M sodium acetate (if aqueous layer is 
500 μl, add 125 μl  of sodium acetate). 
11. Add equivalent volume of ice-cold isopropanol to the sample (if combined volume 
from step 5 is 625 μl, add 625 μl of isopropanol). 
12. Add 3 μg of glycogen and invert tube 5 times to effectively mix. (See Note 4).  
13. Place on ice for 10 minutes. 
14. Centrifuge sample at 4°C and ~21,000 x g for 10 minutes.  
15. Pour off supernatant and resuspend in 1 ml of 70% ethanol, followed by another 
centrifugation at 4°C and ~21,000 x g for 10 minutes.  
16. Pour off supernatant and resuspend the sample in 500 μl of FA Lysis Buffer 
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Sonication 
Materials used: 
• Diagenode Bioruptor Sonicator  
• New England Biolabs 100 bp DNA ladder 
• New England Biolabs 6x loading dye 
1. Nucleic acids should be effectively resuspended to dissolve into the FA Lysis Buffer 
before sonication. Sonication should be completed to form an average fragment size 
of ~500 bp of DNA (See Note 5). 
2. Sonication in a Diagenode Bioruptor can be completed in 2 sessions of 15 minutes 
each, at the medium setting with on and off pulses of 30 seconds (See Note 6).  
3. Prepare a 1.5% agarose gel to analyze the size of DNA fragments of your sonicated 
nucleic acid.  
4. Load nucleic acid into the gel with a 6x loading dye and a separate 100 bp DNA 
ladder to determine fragment size.  
5. Electrophorese at 100 volts until the ladder reaches 2/3 of the way down the gel. 
6. Analyzed gel should indicate an average fragment size of ~500 bases, this is ideal to 
identify R-Loop formation. 
7. Prior to beginning immunoprecipitation, reserve 25 μl of chromatin from each sample 
to use as an input control, or around 5% of the total sample. Store this chromatin for 
use in final analysis (See Note 7). 
8. Each sample will be analyzed using 3 reactions: A non-specific antibody control 
(IgG), a sample with the S9.6 antibody that has been treated by RNaseH (negative 
control) and a sample with the S9.6 antibody (experimental). 
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9. From your sonicated chromatin, isolate 40 μg of nucleic acid for each of these three 
reactions (See Note 8). 
10. To your negative control, add 5 μl of RNase H. To all 3 samples, add the salt 
solution for the RNase H reaction. Incubate all three samples at 37°C on a heat block 
for 1 hour. RNase can be heat inactivated at 65°C for 20 minutes. 
11. To each sample, add FA lysis buffer to raise the total volume to 500 μl.  
S9.6 Immunoprecipitation 
Materials used 
• Anti-Mouse IgG antibody 
• S9.6 DNA-RNA Hybrid antibody 
• Pierce Protein A/G Magnetic Beads 
• DynaMag2 magnetic tube rack 
• Bead Wash Buffer: TBS containing 0.05% Tween 20 
1. Add 10 μg of anti-mouse IgG to the isotype control, and 10 μg of S9.6 antibody to the 
negative and experimental samples. 
2. For each sample including controls, prepare 25 μl of Pierce Protein A/G magnetic 
beads. Wash with 25 μl of bead wash buffer. 
3. Place tubes on a Dynamag 2 magnetic tube rack (or equivalent magnet) to isolate 
beads, then remove and discard supernatant while saving the beads (See Note 9). 
4. Repeat wash with 500 μl of Bead wash buffer, and isolate beads on magnetic rack. 
5. Resuspend beads in 25 μl of FA lysis buffer. 
6. Add beads to each sample and rotate at 4°C for 4 hours.  
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7. After 4-hour rotation, place each tube on the magnetic rack, and pipette away the 
supernatant, saving for future use (See Note 10). 
8. Remove tube from magnetic rack, and softly pipette 500 μl of wash buffer over the 
beads containing the immunoprecipitate. Without vortexing, mix beads to wash.  
9. Place tubes back on magnetic rack and remove the wash buffer without disturbing 
the bead pellet on the side of the tube. 
10. Repeat steps 7 and 8 two more times. 
11. Wash 1x with 500 μl of ice-cold PBS. 
12. If you plan to isolate the RNA fraction, proceed to RNA Extraction.  If you plan to 
isolate the DNA fraction, proceed to DNA Extraction. 
RNA Extraction 
Materials used 
• Tri-Reagent (RNA/DNA/Protein) Isolation reagent 
• QIAGEN RNeasy Minelute Cleanup Kit 
• Tris-EDTA Buffer: 1M Tris pH 8, 0.5M EDTA pH 8, H2O 
1. Resuspend beads in 1 ml of TRI-Reagent, and freeze the sample at -80°C to extract 
RNA from beads (See Note 11) 
2. Thaw sample completely before moving on to the rest of the RNA isolation, usually 
~15 minutes at room temperature (See Note 12). 
3. Add 200 μl of chloroform, followed by vigorous vortexing and mixing by inversion. 
Vortex multiple times, during which two layers will begin to form. 
4. Samples should incubate at room temperature for 10 minutes, after which the two 
phases should be clearly visible. 
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5. Centrifuge at ~21,000 x g for 10 minutes at 4°C. 
6. Transfer the aqueous phase to new eppendorf tubes and add 500 μl of ice cold 
isopropanol and 2 μl of glycogen to each tube (See Note 13). 
7. Mix by inversion and incubate at room temperature for 10 minutes. 
8. Centrifuge at 21,000 x g for 10 minutes at 4°C. Following this spin, a pellet should be 
visible at the bottom of the tube. 
9. Pour off supernatant from each tube and wash with 1 ml ice-cold 75% ethanol. 
10. Centrifuge at 21,000 x g for 10 minutes at 4°C. 
11. Pour off supernatant and let sample air dry for 10 minutes to remove excess 
ethanol. 
12. Resuspend in 100 μl of Tris-EDTA Buffer. 
13. Using the RNeasy MinElute Cleanup Kit, add 350 μl of Buffer RLT to each sample. 
14. Add 250 μl of 100% ethanol to each sample and mix by pipetting up and down. 
15. Transfer each sample to a Minelute column, and centrifuge at 13,500 x g for 30 
seconds. Discard the flow thru following centrifugation. 
16. Add 500 μl of Buffer RPE to the Minelute column, and again centrifuge at 13,500 x g 
for 30 seconds. Again, discard the flow thru. 
17. Add 500 μl of 80% ethanol to each column, and centrifuge for 2 minutes at 13.500 x 
g. Discard the flow thru. 
18. Centrifuge the dry column with the cap open at 13,500 x g for 5 minutes. 
19. Move to a new eppendorf tube for collection and dispose of the previous collection 
tube. 
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20. Add 18 μl of ultrapure water directly to the column. Let the column sit at room 
temperature for 5 minutes, then centrifuge at 13,500 x g for 1 minute (See Note 14). 
21. Discard the column and proceed to cDNA conversion (See Note 15). 
cDNA conversion 
Materials used: 
• Invitrogen Superscript 3 First Strand Synthesis System 
• QIAGEN Qiaquick PCR purification kit 
1. Place 18 μl of RNA from previous step to a strip cap tube for use in a thermal cycler. 
Combine with 1 μl of dNTPs, and 1 μl of Oligo(dt) if your RNA of interest is 
polyadenylated, or 1 μl random hexamers if it is not or you don’t know. 
2. Incubate at 65°C in a thermal cycler for 5 minutes. Then place on ice, or at 0°C for at 
least 1 minute.  
3. To each sample, add 4 μl of 10x RT buffer, 8 μl of 25 mM Magnesium Chloride, 4 μl 
of 1 M DTT, 2 μl of RNaseOUT, and 2 μl of Superscript III RT (See Note 16). 
a. If using Oligo dT, go directly to step 5. If using random hexamer, samples should be 
incubated at 25°C for 10 minutes before proceeding 
4. Incubate at 50°C for 50 minutes, followed by 85°C for 5 minutes. 
5. Add 1 μl of RNase H to each sample and incubate at 37°C for 20 minutes.  
6. Using the QIAquick PCR purification kit, add 105 μl of Buffer PB to each reaction. 
7. Place the mixture of sample and buffer to a QIAquick column and centrifuge at 
13,500 x g for 1 minute. Discard the flow thru. 
8. Add 750 μl of Buffer PE to each column, and centrifuge at 13,500 x g for 1 minute. 
Discard the flow thru. 
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9. Centrifuge the dry column with cap open at 13,500 x g for 1 minute. 
10. Place the column in a fresh eppendorf tube for collection and add 50 μl of Buffer EB 
to the center of the column. 
11. Centrifuge at 13,500 x g for 2 minutes.  
12. Proceed to quantitative PCR or other method of analysis.  
DNA Extraction 
Materials used: 
• Elution Buffer: 100 mM NaHCO3, 1% SDS 
1. Add 120 μl of elution buffer to the beads and rotate for 15 minutes at room 
temperature. 
2. The antibody/DNA complex is now present in the supernatant and separate from the 
beads. Place tubes on the magnetic rack, and isolate supernatant in a new eppendorf 
tube.  
3. Add 5 μl of proteinase K to each tube and allow at least 4 hours (or overnight) of 
incubation in a 65°C water bath. 
4. The following morning, add 500 μl of phenol chloroform and vortex vigorously. 
5. Centrifuge for 5 minutes at 4°C at 21,000 x g. 
6. Remove the top aqueous layer and move to a new eppendorf tube. 
7. Add 125 μl (or 1/4th of total volume of aqueous layer) of 9M sodium acetate. 
8. Add 625 μl (or combined volume of sample and sodium acetate) of 100% isopropanol 
to each sample. 
9. Add 2 μl of glycogen to each sample. 
10. Vortex vigorously and place on ice for 10 minutes. 
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11. Centrifuge for 10 minutes at 4°C at 21,000 x g. 
12. Pour off supernatant and let the pellet air dry. 
13. Resuspend in 50 μl Ultrapure water and proceed to qPCR evaluation. 
Quantitative PCR (qPCR) evaluation 
• ABI Quantstudio 3 or equivalent qPCR platform 
• ABI PowerUP SYBR Green Reaction Mix  
• PCR primers for each unique target region 
1. Dilute samples uniformly to the volume necessary for your PCR reactions using 5 μl 
of sample per reaction (50 μl provides 10 reactions, so if you plan to run 20 reactions, 
dilute all samples to 100 μl total). 
2. Each 25 μl reaction should include: 
a. 12.5 μl of SYBR Green reaction mix 
b. 6.25 μl of Ultrapure water 
c. 1.25 μl of PCR primers at 10 μM concentrations) 
d. 5 μl of sample per reaction 
3. Each sample will run at the following temperatures and cycles to complete the qPCR. 
a. 2 minutes at 50.0°C 
b. 10 minutes at 95.0°C 
c. 40 cycles repeating 
i. 15 seconds at 95.0°C  
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ii. 60 seconds at 60.0°C 
4. Change qPCR settings according to your reagents and qPCR instrument, but these 
settings are applicable to the ABI qPCR system. 
 
Notes 
1. Proteinase K activity can degrade over time, so prepare the R-Loop digestion buffer 
in large quantities without the proteinase K included. Before using the digestion 
buffer, combine the premade buffer with the proteinase K for the most effective 
digestion. 
2. Cell Signaling provides a 10x cell lysis buffer that we used for our FA lysis buffer that 
works great, as opposed to preparing all the reagents. Combine this with the New 
England Biolabs Proteinase K, which is the total buffer used in these reactions. 
3. Excess PBS left in can really affect the function of the NP40 detergent, so pour off 
the supernatant PBS first, and then pull as much off as possible with a pipette to limit 
how much is left in the sample. 
4. This isolation should contain a large amount of nucleic acid, so a visible pellet should 
be present. If not, attempt the isolation again from the original sample. 
5. It is never going to be perfect 500 bp fragments, but keeping your fragments almost 
entirely below the 1200-1500 bp range will significantly reduce your background and 
the number of false positives you will find. Hybrid DNA:RNA formations are almost 
always larger than 50 bases, so if your fragments are mostly around 500 bp, you will 
have a pretty good sample to work with for the immunoprecipitation. 
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6. You absolutely must use a bath sonicator for this step. Using a needle sonicator 
results in a significant decrease in the overall yield recovered. You can even just use 
a cocktail of endonucleases for sonication, but a bath sonicator works most effectively 
and efficiently. The Bioruptor works great at the settings presented, but this step does 
take optimizing, because every sonicator is a little bit different.  
7. The input is necessary for the final calculation for the qPCR determinations, just like a 
standard ChIP experiment. If used for the RNA fraction, it needs to be incorporated 
during RNA isolation immediately starting at step 6.13. If used for the DNA 
determination, it can be incorporated at step 8.3. Otherwise, treat as you would any 
input for a standard ChIP assay. 
8. Another step that could need optimizing: For most ChIP experiments, 25 μg works 
well. With immune cells, I scaled up to 40 μg, and this produced an effective qPCR 
measurement. If you end up with too much background, or not enough signal, 
possibly scaling up or down the initial chromatin per reaction may help. 
9. Pierce Protein A/G magnetic beads work great for this assay, though other brands of 
magnetic A/G beads may also be effective. Agarose beads did not allow for a clean 
enough immunoprecipitation and resulted in too high background Ct values. 
10. Saving the supernatant is not incredibly important, but it can help you verify when 
the experiment failed. If the supernatant nor your experimental sample test positive 
for your gene of interest, then something went wrong before this step. If it is present 
in the supernatant, but not your experimental, then it is most likely negative for 
DNA:RNA hybrid formation. 
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11. Tri-Reagent, or another alternative, Trizol, are both available to complete the RNA 
extraction. No matter which you use, RNA extraction utilizing guanidinium-
thiocyanate-phenol-chloroform will provide the most efficient and accurate results for 
this protocol. 
12. I would advise freeze/thawing 3 times before beginning the experiment, as 
additional freeze thaws could help increase RNA yields by a small amount. At this 
point you are working with a small total amount of nucleic acid, so every bit should be 
preserved as much as possible. 
13. A dyed glycogen, like Glycoblue, makes this step much easier. Unlike the previous 
isolation, this step does not have much material present in comparison. So, using the 
dyed glycogen makes it easier to see if there is any nucleic acid present. 
14. The instructions for the Minelute kit do not include the incubation step with ultrapure 
water on top of the column, but we have found that soaking the column really helps 
maximize RNA recovery. 
15. This is a good time to quantitate your RNA, possibly using a nanodrop in order to 
test if sample is present or not. It will never be a very high concentration, but this is a 
good step to make sure whether anything has gone wrong in your previous steps. 
16. It is by far easier to prepare a master mix for these reagents as opposed to pipetting 
them all individually. I would advise combining before adding to the samples. 
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CHAPTER IV 
 
BROMODOMAIN INHIBITOR JQ1 REVERSIBLY BLOCKS IFN-γ PRODUCTION 
 
Abstract 
As a class, ‘BET’ inhibitors disrupt binding of bromodomain and extra-terminal 
motif (BET) proteins, BRD2, BRD3, BRD4 and BRDT, to acetylated histones preventing 
recruitment of RNA polymerase 2 to enhancers and promoters, especially super-
enhancers, to inhibit gene transcription. As such, BET inhibitors may be useful 
therapeutics for treatment of cancer and inflammatory disease.  For example, the small 
molecule BET inhibitor, JQ1, selectively represses MYC, an important oncogene 
regulated by a super-enhancer. IFN-γ, a critical cytokine for both innate and adaptive 
immune responses, is also regulated by a super-enhancer. Here, we show that JQ1 
represses IFN-γ expression in TH1 polarized cultures, CD4+ memory T-cells, and NK 
cells. JQ1 treatment does not reduce activating chromatin marks at the IFNG locus but 
displaces RNA polymerase II from the locus. Further, IFN-γ expression recovers in 
polarized TH1 cultures following removal of JQ1. Our results show that JQ1 abrogates 
IFN-γ expression, but repression is reversible.  Thus, BET inhibitors may disrupt the 
normal functions of the innate and adaptive immune response.   
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Introduction 
Bromodomain and extraterminal domain (BET) proteins are a family of 
transcriptional mediators, which assist in the recruitment of RNA Polymerase II (RNA pol 
II) to enhancers and promoters 121,158. This family of proteins consists of BRD2, BRD3, 
BRD4, and BRDT. These proteins bind histone acetylated lysine residues via two highly 
conserved amino-terminal bromodomains 159. BRD4 has been extensively studied for its 
role in transcriptional initiation and elongation 120,121,158-161. BRD4 interacts with both the 
mediator complex, and the positive elongation factor B (P-TEFb) at enhancers and 
promoter regions, respectively 121,162. BRD4 is expressed in almost all human tissues, 
and its role in transcription has made it a primary target for possible cancer therapies 
163,164.  
 JQ1 is a bromodomain inhibitor, which selectively binds to the amino-terminal twin 
bromodomains of BET proteins 165. JQ1 treatment displaces BRD4, inhibiting its ability to 
read acetylated lysine residues 166. As a result, JQ1 selectively represses the MYC 
oncogene 167 in a variety of cancer cell lines and animal models of cancer, including acute 
myeloid leukemia 164, Burkitt’s lymphoma 168, and multiple myeloma 167. JQ1 represses 
MYC expression by interrupting the Mediator-BRD4 complexes located in its super-
enhancer region 166,169. A super-enhancer is a cluster of enhancers within close proximity 
that are densely populated by transcription factors, active histone marks, and co-
activators 118,119. Super-enhancers are thought to regulate genes that encode proteins 
that define cell identity as well as proteins that contribute to human disease, including 
cancers and inflammatory disease 123,170. In fact, BET inhibitors, such as JQ1 show 
efficacy in pre-clinical models of cancer as well as autoimmune disease 164,167,168,171–174 . 
 62 
 Despite its potential as a cancer treatment, JQ1 inhibitors repress the expression 
of multiple genes, not only oncogenes 184. For example, JQ1 treatment abrogates 
expression of IFNG by memory T-cells 176.  Interferon gamma (IFN-γ) is a cytokine that 
plays a critical role in both innate and adaptive immunity against viral and bacterial 
infections. IFN-γ is expressed by effector CD4+ (TH1) and CD8+ (TC1) T-cells, memory 
CD4+ and CD8+ T-cells, as well as natural killer (NK) cells and natural killer T (NKT) cells 
176.  Another BET inhibitor, I-BET 762, was found to repress IFN-γ expression by TH1 
cells during development 172. 
 Although BET inhibitors have shown efficacy in a variety of pre-clinical models of 
malignancy, we do not have a complete understanding of its impact on immune cells, nor 
how long any immunosuppressive effects that exist may last. Here, we sought to evaluate 
the ability of JQ1 to inhibit production of IFN-γ by TH1 polarized cultures, CD4+ memory 
T-cells, and NK cells.  Our results demonstrate that JQ1 significantly reduces IFN-γ 
expression in all 3 cells types up to 5 days following treatment. JQ1 does not alter levels 
of activating H3K27 acetylation (H3K27ac) chromatin marks at the IFNG gene locus but 
displaces RNA pol II from the IFNG locus. Finally, inhibition of IFN-γ expression by JQ1 
is not irreversible as ability of TH1 polarized cultures to produce IFN-γ is recovered after 
removal of JQ1.  
 
Materials and Methods 
Cell isolations and culture. TH1 Polarized PBMC Cultures: Total Human PBMCs 
were isolated from healthy control subjects with no chronic or acute conditions using 
Ficoll-Hypaque centrifugation. All subjects included in the study were of Caucasian 
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descent between ages 25-32. PBMCs (106 cells/ml) were stimulated with plate bound 
anti-CD3 (OKT3,CRL-8001, American Type Tissue Collection, ATCC), soluble mouse 
anti-human CD28 (1 g/ml; 555725; BD Biosciences) and IL-12  (10 ng/ ml, BD 
Biosciences) without addition of IL-2 or anti-cytokine neutralizing antibodies essentially 
as previously described 83,141.  PBMCs were cultured in RPMI 1640 media (11875093, 
ThermoFisher) supplemented with 10% fetal bovine serum, penicillin-streptomycin and L-
glutamine at 37oC in 5% CO2 in air. As outlined in Figure 1A, cells were treated with JQ1 
for varied periods of time, followed by a re-stimulation with anti-CD3 for 48 hours.  
CD4+ Memory T-cells: Single cell suspensions were prepared from human spleen.  CD4+ 
memory T-cells were purified by negative selection (Stemcell, 19157). CD4+ memory 
cells (106 cells/ml) were stimulated with anti-CD3 for 24 hours as described in Figure 2A. 
Cells were treated with JQ1 for varied periods of time, and re-stimulated with fresh plate 
bound anti-CD3 for 48 hours. Natural Killer cells: NK cells were activated and expanded 
from human PBMCs using the NK cell activation and expansion kit (Miltenyi Biotec, 130-
094-483) for up to a period of 21 days. NK cells were plated in 3 mL cultures at 106 
cells/ml, and treated with JQ1 as described in Figure 3A. After treatment with JQ1, NK 
cells were stimulated with IL-12 (10 ng/mL: 554613, BD Pharmingen) and IL-18 (10 
ng/mL: 4179-25, Biovision) for 48 hours. JQ1 (SML1524-5MG, Sigma Aldrich) was 
dissolved in DMSO at a final concentration of 10 mM and diluted into complete medium 
for addition to cell cultures. The study was approved by the institutional review board at 
Vanderbilt University Medical Center. Written informed consent was obtained at the time 
of blood sample collection. Spleen cells were obtained from Tennessee Donor Services 
under approved protocols with informed consent. 
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Quantitative Real-Time PCR. Total RNA isolation, cDNA synthesis using poly-A 
selection and analysis by qPCR were performed essentially as previously described 177. 
All expression levels were normalized to GAPDH using the formula 2(GAPDH Ct-target gene Ct). 
Primer pairs used in analysis are provided in supplemental figures. Housekeeping genes 
were evaluated by a different calculation in Figure 4B, to evaluate reference gene quality, 
using the formula (1/target gene Ct)/(1/target gene Ct at 0 nM treatment). These assays 
specifically were normalized to total cDNA concentration of 2 ng/μL. 
MTT-cell Proliferation Assay. MTT assays were performed using the CellTiter 96 
Non-Radioactive Cell Proliferation Assay (G4001, Promega).  Absorbances were 
determined using an EMax plus Microplate Reader at 570 nm. Cell survival was 
calculated by (absorbance of treatment/absorbance at 0 nM). 
Chromatin Immunoprecipitation (ChIP). ChIP procedures were as previously 
described using anti-H3K27ac (ab4729, Abcam) anti-H3K27me (AB6002, Abcam), anti-
RNA Polymerase II (AB817, Abcam), or anti-mouse IgG (SC2357, Santa Cruz) antibodies 
117. DNA was isolated using Pierce Protein A/G magnetic beads (88802, ThermoFisher) 
via phenol chloroform extraction. Isolated chromatin was analyzed using SYBR-Green 
qPCR (Applied Biosystems).  
Enzyme Linked Immunosorbent Assay (ELISA). ELISA was performed 
according to instructions provided by the manufacturer to analyze IFN-γ protein (BD 
Bioscience, 555142).  
Statistics. JQ1 treatments and the corresponding qPCR or ELISA analyses were 
evaluated using a 1-way ANOVA test with Dunnett’s Multiple comparison test for each 
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concentration comparison. ChIP analyses were expressed as fraction of input and 
evaluated using an unpaired t-test with Welch’s correction.  Unless otherwise stated, 
*=P<0.05 and data are represented as mean ± S.D. 
 
Results 
JQ1 represses IFN-γ expression by TH1 cells, memory T-cells and NK cells. 
To determine the impact of JQ1 on IFNG expression by TH1 polarized PBMC cultures, 
we treated cells at multiple time points of cell culture. PBMCs were stimulated under TH1 
polarizing conditions and treated with 50, 150, and 500 nM final concentrations of JQ1 at 
different times during the polarization process, harvested and restimulated with anti-CD3 
(Figure 4-1A).  IFNG transcripts were significantly reduced in cells treated for 24 or 48 
hours with either 150 or 500 nM final concentrations of JQ1 (Figure 4-1B).  IFNG mRNA 
was also reduced in PBMC treated under TH1 polarizing conditions for 4 or 5 days prior 
to JQ1 treatment (Figure 4-1C). Further, we increased the duration of JQ1 treatment to 
3, 4, and 5 days to see if cells would recover IFN-γ expression (Figure 4-1D). In each of 
these treatments, IFNG mRNA was significantly decreased at all concentrations of JQ1 
treatment. Total RNA isolated from cells in culture did not change according to the JQ1 
concentration indicating that JQ1 treatment did not have a significant impact on total 
levels of cellular RNA in the different cultures (Figure 4-1E). These results indicate that 
JQ1 treatment significantly inhibited IFNG mRNA expression by TH1 polarized PBMC 
cultures.  
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Figure 4-1. IFNG RNA transcripts are significantly reduced in TH1 polarized cultures by 
the BET inhibitor JQ1. (A) Experimental design; : period of stimulation with anti-CD3, 
anti-CD28, IL-12, : period of JQ1 treatment, : period of restimulation with anti-
CD3. (B-D) Y-axes are levels of IFNG mRNA relative to GAPDH mRNA, X-axes are treatment 
times with JQ1, N=4 each. (E) Average total RNA isolated from B, C and D cultures at each 
concentration of JQ1, N=12. *=P<0.05 
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We previously demonstrated that acute exposure of CD4+ memory T-cells to JQ1 
prevented induction of IFN-γ in response to anti-CD3 stimulation 178. To expand upon 
these studies, we stimulated CD4+ T memory cells for 24 hours with anti-CD3 to induce 
IFNG mRNA expression, treated cells with varying amounts of JQ1 for varying periods of 
time, and then re-stimulated cultures with anti-CD3 (Figure 4-2A). IFNG mRNA 
expression in memory cells treated with JQ1 for 24 and 48 hours was significantly reduced 
at 150 and 500 nM concentrations of JQ1 (Figure 4-2B). Similarly, when treated for 3, 4, 
or 5 days, IFNG mRNA expression was significantly reduced in CD4+ memory T-cells 
(Figure 4-2C). Total RNA isolated from memory cell cultures was significantly reduced in 
longer term cultures at 500 nM concentrations, which could indicate an impact on cell 
viability or total RNA expression or both (Figure 4-2D). Despite this, IFNG mRNA 
expression was significantly reduced at 150 nM concentrations of JQ1 in CD4+ memory 
T-cells and we found no significant loss of total RNA yield in these cultures. These data 
indicate that JQ1 treatment reduces IFNG mRNA in CD4+ memory T-cells, like TH1 
polarized PBMC cultures.  
 We next evaluated effects of JQ1 treatment on NK cells. NK cells were treated with 
JQ1 for varying periods of time at 50, 150, and 500 nM final concentration and stimulated 
with IL-12 and IL-18 (Figure 4-3A). Like TH1 cells, IFNG expression was significantly 
reduced in NK cells treated with JQ1 (Figure 4-3B).  IFNG mRNA was similarly reduced 
when treated for 3-5 days at 150 and 500 nM concentrations of JQ1 (Figure 4-3C). Total 
RNA isolated from NK cells did not significantly change according to JQ1 treatment, 
indicating cell viability and total cellular RNA yield were not affected by the JQ1 treatments 
(Figure 4-3D). These results indicate that IFN-γ expression was significantly reduced in  
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Figure 4-2. IFNG mRNA expression is significantly reduced in CD4+ T memory cells 
following JQ1 treatment. (A) Experiment design; : period of stimulation with anti-CD3, 
: period of JQ1 treatment, : period of restimulation with anti-CD3. (B, C) Y-axes 
are levels of IFNG mRNA relative to GAPDH mRNA, X-axes are treatment times with JQ1, 
N=4. D) Average total RNA isolated from (B & C) samples at each concentration of JQ1 
treatment N=6. *=P<0.05 
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NK cells following JQ1 treatment, similar to TH1 polarized PBMC cultures and 
memory CD4+ T-cells. 
JQ1 effects on cell viability. We used the ‘MTT assay’ to determine if culture with 
JQ1 affected viability of the differenT-cell types.  We found no loss of viability in TH1 
polarized PBMC, NK, or CD4+ memory T-cell cultures after treatment with concentrations 
of JQ1 that significantly diminished IFNG expression (Figure 4-4A).  As a second control 
experiment, we determined if culture with JQ1 affected expression levels of standard 
‘housekeeping’ genes, GAPDH, HPRT and ACTB.  We found that culture with JQ1 did 
not affect expression levels of GAPDH and HPRT but reduced levels of ACTB by ~25% 
in TH1 polarized PBMC cultures (Figure 4-4B).  We also evaluated effects of culture with 
JQ1 on other genes that encode proteins critical for differentiation and function of TH1, 
NK, and CD4+ memory T-cells, STAT4, TBX21 (T-bet), IL12RB1 and IL12RB2 20.  We 
found that culture with JQ1 did not affect expression of STAT4 and TBX21 but did cause 
a reduction of IL12RB1 and IL12RB2 expression levels (Figure 4-4C).  Inhibition of 
expression of IL12RB1 and IL12RB2 by JQ1 was similar in magnitude to inhibition of 
expression of IFNG.  We also examined expression of genes that encode proteins 
participating in the biologic activity of bromodomain-containing proteins, including MED1, 
part of the mediator complex, HEXIM1, part of the P-TEFb complex, and POLR2A, part 
of the RNA polymerase 2 complex 20. We found that culture with JQ1 did not alter 
expression levels of these genes (Figure 4-4D).   Thus, under conditions where culture 
with JQ1 resulted in a marked reduction in IFNG expression levels, changes in viability, 
expression of ‘housekeeping’ genes, of STAT4 and TBX21, and of MED1, HEXIM1 and  
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Figure 4-3. Induction of NK cell IFNG mRNA expression is reduced after JQ1 treatment. 
(A) Experimental design; : period of JQ1 treatment, : period of stimulation with IL-
12 and IL-18.  (B, C) Y-axes are levels of IFNG mRNA relative to GAPDH mRNA, X-axes are 
treatment times with JQ1, N=4. (D) Average total RNA isolated from samples from B and C at 
each concentration of JQ1, N=8. *=P<0.05 
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Figure 4-4. JQ1 treatment is not cytotoxic to TH1 polarized PBMC cultures but does 
repress other genes besides IFNG. (A). Cell cultures were treated with the indicated 
concentrations of JQ1.  Viability was determined after 48 hours using the MTT assay.   
Results are expressed as percent of the no treatment control, N=4 (B) TH1 polarized PBMC 
cultures were treated with JQ1 for 48-hour JQ1.  RNA was isolated and analyzed by qPCR. 
Reactions were standardized to 2 ng/μL of cDNA and calculated relative to 0 nM control. 
N=3 (C-D) As in B, but qPCR results were calculated relative to GAPDH. 
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POLR2A were not observed. However, genes that encode the IL-12 receptor beta 
subunits were equally sensitive to culture with JQ1 as was IFNG.   
JQ1 abrogates RNA Pol II binding to the IFNG locus. We next sought to 
investigate epigenetic changes throughout the IFNG locus and how chromatin marks may 
be modified by JQ1 treatment. The IFNG gene locus has a large network of enhancers 
similar to a super-enhancer (Figure 4-5A) 117,123,178,179. These regions are marked by 
H3K27ac, which make the region more accessible to binding transcription factors and Pol 
II 119,180. We cultivated TH1 polarizing PBMC cultures for 5 days, treated with 150 and 
300 nM final concentrations JQ1 for 24 hours and isolated chromatin for ChIP assays. 
We evaluated regions of the IFNG locus previously shown to be highly enriched for 
H3K27ac marks and recruitment of RNA Pol II 24. We found that JQ1 treatment did not 
significantly change the levels of H3K27ac marks throughout the IFNG locus (Figure 4-
5B).  We also analyzed H3K27me3 marks, indicators of an inactive enhancer 181, and 
found that chromatin within the IFNG locus showed no increase in repressive H3K27me3 
marks following JQ1 treatment (Figure 4-5C). We similarly performed ChIP assays for 
RNA Pol II throughout the IFNG locus. JQ1 treatment caused a significant decrease in 
the binding of RNA Pol II both upstream and downstream of the IFNG gene (Figure 4-
5D). Therefore, JQ1 effectively displaced bound RNA Pol II from the IFNG locus but did 
not change levels of either H3K27ac or H3K27me epigenetic marks at the IFNG locus. 
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Figure 4-5. JQ1 treatment does 
not alter H3K27ac or H3K27me 
marks but abrogates RNA pol2 
binding at the IFNG locus. (A) 
Schematic of predicted enhancer 
locations around IFNG locus. 
Numbers and arrows represent 
points distance in Kb from 
transcription start site of IFNG 
gene. Predicted super-enhancers 
in red ( ) and typical 
enhancers in grey ( ), according 
to 20,108,114,169. (B) TH1 cells were 
cultured as in Figure 1C. ChIP-
qPCR assays were performed to 
measure H3K27ac levels at the 
IFNG locus. Positions, X-axis, are 
relative to the IFNG transcription 
start site (e.g., IFNGR-160 = 
160Kb downstream of TSS), Y-axis 
is fraction of input DNA, N=3. Each 
region evaluated for H3K27ac was 
significantly higher than IgG control 
but did not vary according to JQ1 
concentration.  (C) as in A, but 
ChIP-qPCR assays were 
performed to measure H3K27me 
levels, N=3. No H3K9me3 ChIP 
result was significantly different 
from the IgG control. (D) as in A, 
but ChIP-qPCR assays were 
performed to measure RNA pol II 
recruitment, N=3. RNA pol II ChIP 
0 nM controls were significantly 
different from IgG controls at each 
location. Similarly, RNA pol II ChIP 
0 nM controls were significantly 
different from JQ1 treatments at 
every location.  
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  TH1 polarized cultures recover their ability to produce IFN-γ after removing 
JQ1. JQ1’s half-life is only 0.9 hours after intravenous injection, or 1.4 hours when 
administered orally 169. However, the half-life in tissue culture is not well understood, and 
we wanted to determine if cells could recover their functions when JQ1 was removed from 
culture. We treated TH1 polarized PBMC cultures for 24 or 48 hours with JQ1 on day 5  
 
 
 
 
 
 
Figure 4-6. IFNG expression 
recovers following JQ1 removal. 
(A).  After 5 days. TH1 cultures 
were treated with JQ1 at 150 and 
300 nM final concentrations for 24 
or 48 hours. Cells were either 
restimulated with anti-CD3 for 48 
hours, or washed with new media 
lacking JQ1 and restimulated with 
anti-CD3 for 48 hours. RNA was 
isolated and IFNG analyzed by 
qPCR and normalized to GAPDH, 
N =3. (B) As in A except culture 
fluids were harvested and IFN-γ 
levels determined by ELISA, N=3.  
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of development, similar to Figure 1C. Following treatment, cells were either washed and 
plated with fresh media lacking JQ1 or cultures were continued in the presence of JQ1.  
We found that IFNG mRNA transcripts recovered to pre-treatment levels in TH1 polarized 
cultures after being washed and re-plated in fresh media (Figure 6A). We completed a 
similar experiment but analyzed IFN-γ protein by ELISA. Similarly, IFN-γ was reduced in 
cultures treated with JQ1 (Figure 6B), but IFN-γ production also recovered following a 
wash and re-plating with fresh media, similar to the mRNA results. These results indicate 
that IFNG mRNA and protein levels are reduced following JQ1 treatment but recover to 
pre-treatment levels following removal of JQ1.  
 
Discussion 
 At nanomolar concentrations, the BET inhibitor, JQ1, inhibits expression of IFNG 
mRNA and IFN-γ protein by TH1 polarized cultures, memory CD4+ T-cells, and NK cells.  
Under these conditions, JQ1 does not interfere with presence of extensive activating 
H3K27ac marks across the IFNG locus nor does JQ1 induce formation of repressive 
H3K27me marks across the locus.  Rather, JQ1 treatment results in almost complete loss 
of RNA Pol II recruitment across the IFNG locus.  Further, effects of JQ1 are reversible 
and removal of JQ1 by media replacement results in complete recovery of IFNG mRNA 
and IFN-γ protein expression by effector TH1 cells.  Our results are consistent with a 
model whereby JQ1 inhibition of IFNG expression by TH1 polarized cultures, memory 
CD4+ T-cells and NK cells results from almost complete loss of RNA Pol II recruitment 
across the IFNG locus. Further, removal of JQ1 allows BET proteins to rebind to the locus 
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and re-establish RNA Pol II recruitment across the IFNG locus resulting in efficient IFNG 
expression. 
 BET inhibitors disrupt function of both typical-enhancers and super-enhancers 
169,182-184.  The general view is that functions of super-enhancers and genes driven by 
super-enhancers are more sensitive to effects of BET inhibitors than typical enhancers 
169.  The IFNG locus is composed of two large enhancers, each spanning >30 kb, and 
these have been designated super-enhancers in different studies 113,119. Almost complete 
inhibition of IFNG expression is achieved at nanomolar concentrations of JQ1. MYC and 
downstream c-MYC functions and expression, which require function of a nearby super-
enhancer, are also inhibited at similar nanomolar concentrations of JQ1 168,169,174.  Thus, 
IFNG most likely also falls into the class of genes requiring super-enhancers for their 
expression that also exhibit high sensitivity to BET inhibitors, such as JQ1. 
 IFN-γ plays a critical role in the adaptive immune response to control infection by 
intracellular pathogens, including bacteria and viruses, during both initial effector 
responses and memory responses to infection, as well as malignant transformation and 
growth 166,175-178. Major sources of IFN-γ include NK/NKT-cells and T-cells.  When 
NK/NKT-cells immigrate to the periphery, activating epigenetic markings at the IFNG 
locus already exist and these cells are fully capable of producing IFN-γ in response a 
variety of extracellular stimuli 177,185,186.  In contrast, once in the periphery, naïve T-cells 
have to endure additional developmental programs to produce the required activating 
epigenetic markings at the IFNG locus to allow efficient IFN-γ production in response to 
stimulation by antigen 187-189. Thus, it might be expected that treatment with BET 
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inhibitors, such as JQ1, in-vivo, may significantly impair both innate and adaptive arms of 
immunity that play critical roles controlling infection by intracellular pathogens. 
 BET inhibitors function by displacing BET proteins from acetylated lysine motifs, 
but do not directly reverse the chromatin marks 167,190,191. The repression of IFNG in TH1 
polarizing cultures match this model of regulation, as indicated by a continued presence 
of H3K27ac marks, lack of formation of repressive H3K27me3 marks and displacement 
of RNAPol II from the IFNG locus following JQ1 treatment. However, IFNG expression 
recovered after removing JQ1 from the cultures at both concentrations. These results 
indicate that immunosuppressive effects of BET inhibitors, like JQ1, may be reversible.  
Certain BET inhibitors have shown very good efficacy in various pre-clinical models of 
cancer and inflammatory disease 164,167,168,171-174.  It seems likely that BET inhibitors will 
therefore move forward to actual human clinical studies to treat various malignancies as 
well as inflammatory diseases. Our results suggest that BET inhibitors may significantly 
impair both innate and adaptive arms of the immune response, but these effects are 
reversible. The repression of IFNG by JQ1 treatment is observed in the major IFN-γ 
producing cell types. It remains to be determined if inhibition of the immune response by 
BET inhibitors will limit their therapeutic usefulness.   
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CHAPTER V 
 
GENERAL DISCUSSION AND CONCLUSION 
 
The immune system is one of the diverse cell systems in human body. In order to 
respond to constantly evolving pathogens, the cells of the immune system must present 
an equally dynamic response. Diverse cell lineages require a complex regulatory 
network to activate and repress the appropriate genes. The exact mechanisms 
controlling gene regulation and cell identity in many immune cells are still unknown. The 
work presented attempts to understand some of the mechanisms regulating T-helper 
cell polarization, and how similar mechanisms may regulate the diverse cells of the 
immune system. The goal of these experiments was to understand the impact of 
epigenetic factors on the expression of T-helper cell specific gene expression and their 
role in polarization. 
 In the second chapter we demonstrated GATA3-AS1, the divergent lncRNA 
partner of GATA3, was necessary for effective Gata3 expression and subsequent TH2 
polarization. Gata3 regulates cytokine expression by modifying the chromatin landscape 
in each of the TH2 specific cytokines but binds the promoters of IL5 and IL13 33. In 
previous work, IL-5 and IL-13 were reduced following Gata3 knockdown in established 
TH2 cells, but IL-4 was mostly unchanged 31. These results indicate GATA3-AS1 
primarily acts by regulating the GATA3 locus and not the cytokine genes directly. The 
TH2LCRR lncRNA is similarly required for the effective transcription of the hallmark TH2 
cytokines but acts by modifying the chromatin landscape within the TH2 cytokine gene 
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locus 117. GATA3-AS1 is also sufficient to activate Gata3 expression within TH0 cells 
but cannot induce TH2 polarization. TH2 cell development requires other cofactors, like 
STAT6, so Gata3 alone cannot activate the downstream cytokine expression 31. GATA3 
transcription in response to exogenous GATA3-AS1 indicates a function for the lncRNA 
transcript, as opposed to the act of transcription.  
 In our next set of experiments, we demonstrated two molecular interactions for 
GATA3-AS1: the association with WDR5 and the formation of an R-loop. LncRNAs like 
GATA3-AS1 are necessary to recruit WDR5 or other chromatin modifying complexes to 
modify its own gene locus, as well as the GATA3 gene locus. The R-loop formed by 
GATA3-AS1 occurs within its own gene locus and may act to anchor GATA3-AS1 to the 
GATA3-AS1-GATA3 locus prior to interacting with WDR5. Both molecular interactions 
led us to a combined model of regulation (Figure 5-1). The model presented matches 
previous reports of the known interactions between WDR5 and the lncRNA HOTTIP 77, 
but additional experiments are necessary to demonstrate a direct interaction between 
GATA3-AS1 and WDR5. An alternative model might be that the GATA3-AS1 transcript 
may stimulate the catalytic activity of MLL instead of recruiting the complex to 
chromatin. Initial transcription and R-loop formation may allow a more receptive histone 
conformation and increase methyltransferase activity. Additionally, the R-loop formed by 
GATA3-AS1 may be the binding target of WDR5. GADD45A is an epigenetic reader 
which binds specifically to R-loops to recruit the demethylase TET1 192. GADD45A 
recognizes the R-loop formation and openly accessible chromatin but cannot directly 
bind to the lncRNA alone.  
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A 
B
C 
D 
Figure 5-1. MLL complex Recruitment by GATA3-AS1. Proposed model by which 
GATA3-AS1 recruits the MLL methyltransferase to modify chromatin surrounding the 
GATA3-AS1 and GATA3 gene locus. A) Initial expression of GATA3-AS1 and GATA3 begins 
by STAT6 binding to the shared promoter region. B) RNA Pol II transcribes GATA3-AS1. C) 
GATA3-AS1 forms an R-Loop within the 5’ and central region of its gene locus. D) GATA3-
AS1 binds and recruits the MLL protein complex via WDR5 to apply H3K4me3 marks 
throughout the gene locus and make both gene loci more accessible.  
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In the third chapter, we describe an optimized assay for the isolation and 
evaluation of R-loops. The DRIP (DNA:RNA immunoprecipitation) assay is based on the 
development of the S9.6 antibody which specifically targets R-Loops. Reliable assays 
for evaluation of R-loops are increasingly important as more evidence connects 
lncRNAs and R-loop formation. The optimized assay described in this chapter is a 
significant contribution to the functional analysis of R-loops. 
In the fourth chapter, we demonstrate that IFN-γ expression in multiple cell types 
is inhibited by disruption of super-enhancer function via BRD4 displacement. JQ1 
treatment, the bromodomain inhibitor, did not disrupt most housekeeping genes or 
genes that encode proteins required for transcriptional function, but does disrupt 
expression of multiple TH1 lineage specific genes that play important roles in IFN-γ 
production. Resting NK cells are capable of IFN-γ expression hours after stimulation, 
while naive T cells must undergo extensive chromatin rearrangement to make the IFNG 
gene locus more permissive for transcription 176. Effector memory T cells retain many of 
these epigenetic modifications to more rapidly respond to stimulus and initiate IFN-γ 
production. JQ1 treatment disrupted IFN-γ expression in each of these cell types, 
suggesting a shared mechanism of regulation. We conclude that the IFNG locus is 
regulated in each of these cell types by a common super-enhancer due to shared 
sensitivity to JQ1. 
In subsequent experiments, we found bromodomain inhibition by JQ1 does not 
modify the chromatin landscape around IFNG in TH1 cells and IFNG repression is 
reversible. The IFNG gene locus did not lose permissive H3K27ac, nor gain repressive 
H3K27me following treatment with JQ1. BRD4 binds to RNA Pol II and recruits RNA Pol 
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II to enhancers, which was displaced following JQ1 inhibition 121. When JQ1 treatment is 
removed by washing cells in fresh media, IFN-γ expression recovers within 48 hours. 
Therefore, we conclude the immunosuppressive effects of JQ1 are not permanent in 
TH1 cells. 
 
Dual function of divergent lncRNAs 
Initial research of lncRNAs has focused on which cell types express these unique 
transcripts, and most have been accomplished by RNA sequencing.  The functions of 
individual lncRNA transcripts are still mostly not understood, as our classifications of 
lncRNAs are based on how close they are located to mRNA genes. Divergent lncRNAs 
make up a significant portion of annotated lncRNAs in the human genome. Our study of 
GATA3-AS1 has identified two molecular interactions that are not unique by themselves 
but are novel for a single divergent transcript. LncRNAs are known to bind WDR5, 
amongst many other chromatin modifying complexes 77. A few others form R-Loops 
within their own gene locus 93-95. The combined interaction, indicating a 
DNA/RNA/protein complex could provide insight into a conserved mechanism for 
divergent lncRNAs. The shared promoter region between a divergent lncRNA gene and 
its mRNA gene partner are typically < 1kb. Abrogation of GATA3-AS1 transcript levels 
by siRNA removes permissive acetylation marks from both its own gene region, and the 
5’ portion of the GATA3 mRNA gene. The R-loop formation within GATA3-AS1 and 
WDR5 binding could allow efficient recruitment of the MLL methyltransferase and other 
chromatin complexes to both genes. A similar mechanism could be possible for RNAs 
binding to the repressive PRC2 complex, which also has numerous lncRNA binding 
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partners 85. Despite known interactions between lncRNAs and their protein partners, the 
capacity to attract those complexes to specific regions in the genome is still not well 
understood. R-loop formation could represent the anchoring mechanism for targeted 
protein recruitment. Future studies of protein bound lncRNAs should incorporate R-loop 
detection as a possible mechanism for anchoring a given regulatory lncRNA to its target 
gene locus.  
Unlike mRNAs, whose triplet codon structure defines the protein product that will 
eventually be formed, lncRNAs still lack identified motifs that represent functional 
regions. Recent work on Braveheart 193 and Hottip 82 have begun to identify specific 
nucleotide sequences within a lncRNA that contribute to their function of binding 
chromatin modifying complexes. The broad array of lncRNAs that bind to complexes 
like WDR5 and PRC2 do not have a large consistent sequence motif but could share a 
common secondary structure to interact with these protein complexes. The interface 
between lncRNAs and their binding partners could be the key to understand how so 
many variable lncRNAs could share few conserved binding partners.  
 
Immune cell fate is dependent on lncRNAs 
 LncRNAs have recently been described as “the master regulators of cell fate.” 
Unique lncRNAs in distinct T-cell types, like IFNG-AS1, GATA3-AS1, and TH2LCRR, 
are necessary for T-cell polarization and effector cytokine expression  117. Lineage-
specific lncRNAs have been identified in each T-cell subset including some that may 
regulate major regulatory factors in TH17 and Tfh cells. GATA3-AS1 is over-expressed 
in PBMCs from patients with seasonal allergic rhinitis 132, and our work demonstrated 
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that the transcript alone can induce the expression of GATA3, and reduction in GATA3-
AS1 reduces IL-5 expression, a primary cytokine involved in allergic asthma. GATA3-
AS1 could be targeted to reduce allergic inflammation directly within the TH2 cells. 
CD4+ T-cells play important roles in numerous autoimmune disorders including 
rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus, and each of 
these T-cell lineages express unique lncRNAs which could represent potential 
therapeutic targets to modulate immune responses and treat autoimmunity 194. 
 
JQ1 represses cytokines and receptors, but not master transcription factors 
Super-enhancers primarily associate with lineage defining genes in developing 
cells 117,118. In hematopoietic cells, 26% of single nucleotide polymorphisms (SNPs) 
associated with rheumatoid arthritis were located within predicted super-enhancers, 
along with over 30% associated with multiple sclerosis and type 1 diabetes 123. JQ1 and 
other bromodomain inhibitors have strong anti-inflammatory properties and exhibit 
encouraging effects in-vitro and in and in mouse models of rheumatic disease 171-173. 
Bromodomain inhibition by JQ1 reduces expression of IFN-γ in multiple cell lineages 
and the cytokine receptors IL12RB1 and IL12RB2 in TH1 cells. However, the primary 
transcription factors in TH1 cells, T-bet and Stat4, are not reduced by JQ1 treatment. 
Each of these genes has a related super-enhancer according to predictive models and 
chip-seq experiments 123. This represents a disconnection between the predicted model 
of super-enhancer regulation and genes repressed by bromodomain inhibitors. Key 
regulatory nodes in CD4+ T-cells, like the TH2LCR, are located around cytokine and 
cytokine receptor genes, representing possible variations in super-enhancers which 
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may be more sensitive to bromodomain inhibition. Analysis of the full transcriptome in 
JQ1 treated TH1, TH2, and TH17 cells will provide a delineation between BET inhibitor 
sensitive and resistant genes. Identification of BET-inhibition sensitive genes may 
represent a strategy to identify critical immune-response genes and, as such, may help 
identify genes and their protein or lncRNA products that may represent attractive targets 
for the treatment of immune-mediated diseases, such as autoimmune and allergic 
diseases, as well as provide new insights into how super-enhancers may regulate their 
target genes.  
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